

**PCT**WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau


## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 :  C07D 217/24, 237/30, 221/16, 221/12, A61K 31/47, C07D 491/04, 495/04, 498/04, 513/04, 495/14, 498/14, 401/12, 487/04 // (C07D 491/04, 307:00, 221:00) (C07D 495/04, 333:00, 221:00)		A1	(11) International Publication Number: <b>WO 99/11623</b>  (43) International Publication Date: 11 March 1999 (11.03.99)
(21) International Application Number: PCT/US98/18184		(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BI, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).	
(22) International Filing Date: 2 September 1998 (02.09.98)		Published <i>With international search report.</i>	
(30) Priority Data: 08/922,520 3 September 1997 (03.09.97) US 09/079,513 15 May 1998 (15.05.98) US 09/145,179 1 September 1998 (01.09.98) US			
(71) Applicant: GUILFORD PHARMACEUTICALS INC. [US/US]; 6611 Tributary Street, Baltimore, MD 21224 (US).			
(72) Inventors: JACKSON, Paul, F.; 102 Glenmore Court, Bel Air, MD 21014 (US). MACLIN, Keith, M.; 5005 Remmell Avenue, Baltimore, MD 21206 (US). ZHANG, Jie; 8513 High Timber Court, Ellicott City, MD 21043 (US).			
(74) Agent: NATH, Gary, M.; Nath & Associates, 6th floor, 1030 15th Street, N.W., Washington, DC 20005 (US).			

## (54) Title: THIOALKYL COMPOUNDS, METHODS, AND COMPOSITIONS FOR INHIBITING PARP ACTIVITY

## (57) Abstract

A compound of formula (I) or a pharmaceutically acceptable salt, hydrate, ester, solvate, prodrug, metabolite, stereoisomer, or mixtures thereof, wherein: R<sup>1</sup> is lower alkyl, lower alkenyl or lower alkynyl; R<sup>9</sup>, when present, is hydrogen or lower alkyl; Y represents the atoms necessary to form a fused 5- to 6-membered ring that is aromatic or nonaromatic and carbocyclic or heterocyclic; Z is (i) -CHR<sup>2</sup>CHR<sup>3</sup>- where R<sup>2</sup> and R<sup>3</sup> are independently hydrogen, alkyl, aryl or aralkyl; (ii) -R<sup>6</sup>C=CR<sup>3</sup>- where R<sup>6</sup> and R<sup>3</sup> are independently hydrogen, lower alkyl, aryl, aralkyl, chlorine, bromine or -NR<sup>7</sup>R<sup>8</sup>, where R<sup>7</sup> and R<sup>8</sup> are independently hydrogen or lower alkyl, or, R<sup>6</sup> and R<sup>3</sup>, taken together, form a fused 5- to 6-membered ring that is aromatic or nonaromatic and carbocyclic or heterocyclic; (iii) -R<sup>2</sup>C=N-; (iv) -CR<sup>2</sup>(OH)-NR<sup>7</sup>-; or (v) -C(O)-NR<sup>7</sup>.



**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

**THIOALKYL COMPOUNDS, METHODS, AND COMPOSITIONS  
FOR INHIBITING PARP ACTIVITY**

**BACKGROUND OF THE INVENTION**

5       1. Field of the Invention

The present invention relates to inhibitors of the nucleic enzyme poly(adenosine 5'-diphospho-ribose) polymerase ["poly(ADP-ribose) polymerase" or "PARP", which is also sometimes called "PARS" for poly(ADP-ribose) synthetase]. More 10 particularly, the invention relates to the use of PARP inhibitors to prevent and/or treat tissue damage resulting from cell damage or death due to necrosis or apoptosis; neural tissue damage resulting from ischemia and reperfusion injury; neurological disorders and neurodegenerative diseases; to 15 prevent or treat vascular stroke; to treat or prevent cardiovascular disorders; to treat other conditions and/or disorders such as age-related macular degeneration, AIDS and other immune senescence diseases, arthritis, atherosclerosis, cachexia, cancer, degenerative diseases of skeletal muscle 20 involving replicative senescence, diabetes, head trauma, immune senescence, inflammatory bowel disorders (such as colitis and Crohn's disease), muscular dystrophy, osteoarthritis, osteoporosis, chronic and acute pain (such as neuropathic pain), renal failure, retinal ischemia, septic shock (such as 25 endotoxic shock), and skin aging; to extend the lifespan and proliferative capacity of cells; to alter gene expression of senescent cells; or to radiosensitize hypoxic tumor cells.

2. Description of the Prior Art

30       Poly(ADP-ribose) polymerase ("PARP") is an enzyme located in the nuclei of cells of various organs, including muscle, heart and brain cells. PARP plays a physiological role in the repair of strand breaks in DNA. Once activated by damaged DNA fragments, PARP catalyzes the attachment of up to 100 ADP- 35 ribose units to a variety of nuclear proteins, including

histones and PARP itself. While the exact range of functions of PARP has not been fully established, this enzyme is thought to play a role in enhancing DNA repair.

During major cellular stresses, however, the extensive activation of PARP can rapidly lead to cell damage or death through depletion of energy stores. Four molecules of ATP are consumed for every molecule of NAD (the source of ADP-ribose) regenerated. Thus, NAD, the substrate of PARP, is depleted by massive PARP activation and, in the efforts to re-synthesize NAD, ATP may also be depleted.

It has been reported that PARP activation plays a key role in both NMDA- and NO-induced neurotoxicity, as shown by the use of PARP inhibitors to prevent such toxicity in cortical cultures in proportion to their potencies as inhibitors of this enzyme (Zhang et al., "Nitric Oxide Activation of Poly(ADP-Ribose) Synthetase in Neurotoxicity", *Science*, 263:687-89 (1994)); and in hippocampal slices (Wallis et al., "Neuroprotection Against Nitric Oxide Injury with Inhibitors of ADP-Ribosylation", *NeuroReport*, 5:3, 245-48 (1993)). The potential role of PARP inhibitors in treating neurodegenerative diseases and head trauma has thus been known. Research, however, continues to pinpoint the exact mechanisms of their salutary effect in cerebral ischemia, (Endres et al., "Ischemic Brain Injury is Mediated by the Activation of Poly(ADP-Ribose) Polymerase", *J. Cereb. Blood Flow Metabol.*, 17:1143-51 (1997)) and in traumatic brain injury (Wallis et al., "Traumatic Neuroprotection with Inhibitors of Nitric Oxide and ADP-Ribosylation, *Brain Res.*, 710:169-77 (1996)).

It has been demonstrated that single injections of PARP inhibitors have reduced the infarct size caused by ischemia and reperfusion of the heart or skeletal muscle in rabbits. In these studies, a single injection of the PARP inhibitor, 3-amino-benzamide (10 mg/kg), either one minute before occlusion or one minute before reperfusion, caused similar reductions in

infarct size in the heart (32-42%). Another PARP inhibitor, 1,5-dihydroxyisoquinoline (1 mg/kg), reduced infarct size by a comparable degree (38-48%). Thiemermann et al., "Inhibition of the Activity of Poly(ADP Ribose) Synthetase Reduces Ischemia-Reperfusion Injury in the Heart and Skeletal Muscle", Proc. Natl. Acad. Sci. USA, 94:679-83 (1997). This finding has suggested that PARP inhibitors might be able to salvage previously ischemic heart or skeletal muscle tissue.

PARP activation has also been shown to provide an index of damage following neurotoxic insults by glutamate (via NMDA receptor stimulation), reactive oxygen intermediates, amyloid  $\beta$ -protein, n-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and its active metabolite N-methyl-4-phenylpyridine (MPP $^{+}$ ), which participate in pathological conditions such as stroke, Alzheimer's disease and Parkinson's disease. Zhang et al., "Poly(ADP-Ribose) Synthetase Activation: An Early Indicator of Neurotoxic DNA Damage", J. Neurochem., 65:3, 1411-14 (1995). Other studies have continued to explore the role of PARP activation in cerebellar granule cells in vitro and in MPTP neurotoxicity. Cosi et al., "Poly(ADP-Ribose) Polymerase (PARP) Revisited. A New Role for an Old Enzyme: PARP Involvement in Neurodegeneration and PARP Inhibitors as Possible Neuroprotective Agents", Ann. N. Y. Acad. Sci., 825:366-79 (1997); and Cosi et al., "Poly(ADP-Ribose) Polymerase Inhibitors Protect Against MPTP-induced Depletions of Striatal Dopamine and Cortical Noradrenaline in C57B1/6 Mice", Brain Res., 729:264-69 (1996).

Neural damage following stroke and other neurodegenerative processes is thought to result from a massive release of the excitatory neurotransmitter glutamate, which acts upon the N-methyl-D-aspartate (NMDA) receptors and other subtype receptors. Glutamate serves as the predominate excitatory neurotransmitter in the central nervous system (CNS). Neurons release glutamate in great quantities when they are deprived of

oxygen, as may occur during an ischemic brain insult such as a stroke or heart attack. This excess release of glutamate in turn causes over-stimulation (excitotoxicity) of N-methyl-D-aspartate (NMDA), AMPA, Kainate and MGR receptors. When 5 glutamate binds to these receptors, ion channels in the receptors open, permitting flows of ions across their cell membranes, e.g.,  $\text{Ca}^{2+}$  and  $\text{Na}^+$  into the cells and  $\text{K}^+$  out of the cells. These flows of ions, especially the influx of  $\text{Ca}^{2+}$ , cause overstimulation of the neurons. The over-stimulated 10 neurons secrete more glutamate, creating a feedback loop or domino effect which ultimately results in cell damage or death via the production of proteases, lipases and free radicals. Excessive activation of glutamate receptors has been implicated in various neurological diseases and conditions including 15 epilepsy, stroke, Alzheimer's disease, Parkinson's disease, Amyotrophic Lateral Sclerosis (ALS), Huntington's disease, schizophrenia, chronic pain, ischemia and neuronal loss following hypoxia, hypoglycemia, ischemia, trauma, and nervous insult. Recent studies have also advanced a glutamatergic 20 basis for compulsive disorders, particularly drug dependence. Evidence includes findings in many animal species, as well as, in cerebral cortical cultures treated with glutamate or NMDA, that glutamate receptor antagonists block neural damage following vascular stroke. Dawson et al., "Protection of the 25 Brain from Ischemia", *Cerebrovascular Disease*, 319-25 (H. Hunt Batjer ed., 1997). Attempts to prevent excitotoxicity by blocking NMDA, AMPA, Kainate and MGR receptors have proven difficult because each receptor has multiple sites to which glutamate may bind. Many of the compositions that are 30 effective in blocking the receptors are also toxic to animals. As such, there is no known effective treatment for glutamate abnormalities.

The stimulation of NMDA receptors, in turn, activates the enzyme neuronal nitric oxide synthase (NNOS), which causes the

formation of nitric oxide (NO), which more directly mediates neurotoxicity. Protection against NMDA neurotoxicity has occurred following treatment with NOS inhibitors. See Dawson et al., "Nitric Oxide Mediates Glutamate Neurotoxicity in Primary Cortical Cultures", Proc. Natl. Acad. Sci. USA, 88:6368-71 (1991); and Dawson et al., "Mechanisms of Nitric Oxide-mediated Neurotoxicity in Primary Brain Cultures", J. Neurosci., 13:6, 2651-61 (1993). Protection against NMDA neurotoxicity can also occur in cortical cultures from mice with targeted disruption of NNOS. See Dawson et al., "Resistance to Neurotoxicity in Cortical Cultures from Neuronal Nitric Oxide Synthase-Deficient Mice", J. Neurosci., 16:8, 2479-87 (1996).

It is known that neural damage following vascular stroke is markedly diminished in animals treated with NOS inhibitors or in mice with NNOS gene disruption. Iadecola, "Bright and Dark Sides of Nitric Oxide in Ischemic Brain Injury", Trends Neurosci., 20:3, 132-39 (1997); and Huang et al., "Effects of Cerebral Ischemia in Mice Deficient in Neuronal Nitric Oxide Synthase", Science, 265:1883-85 (1994). See also, Beckman et al., "Pathological Implications of Nitric Oxide, Superoxide and Peroxynitrite Formation", Biochem. Soc. Trans., 21:330-34 (1993). Either NO or peroxynitrite can cause DNA damage, which activates PARP. Further support for this is provided in Szabó et al., "DNA Strand Breakage, Activation of Poly(ADP-Ribose) Synthetase, and Cellular Energy Depletion are Involved in the Cytotoxicity in Macrophages and Smooth Muscle Cells Exposed to Peroxynitrite", Proc. Natl. Acad. Sci. USA, 93:1753-58 (1996).

Zhang et al., U.S. Patent No. 5,587,384 issued December 30, 1996, discusses the use of certain PARP inhibitors, such as benzamide and 1,5-dihydroxy-isoquinoline, to prevent NMDA-mediated neurotoxicity and, thus, treat stroke, Alzheimer's disease, Parkinson's disease and Huntington's disease. However, it is has now been discovered that Zhang et al. may

have been in error in classifying neurotoxicity as NMDA-mediated neurotoxicity. Rather, it may have been more appropriate to classify the *in vivo* neurotoxicity present as glutamate neurotoxicity. See Zhang et al. "Nitric Oxide

5 Activation of Poly(ADP-Ribose) Synthetase in Neurotoxicity", *Science*, 263:687-89 (1994). See also, Cosi et al., Poly(ADP-Ribose) Polymerase Inhibitors Protect Against MPTP-induced Depletions of Striatal Dopamine and Cortical Noradrenaline in C57Bl/6 Mice", *Brain Res.*, 729:264-69 (1996).

10 It is also known that PARP inhibitors affect DNA repair generally. Cristovao et al., "Effect of a Poly(ADP-Ribose) Polymerase Inhibitor on DNA Breakage and Cytotoxicity Induced by Hydrogen Peroxide and  $\gamma$ -Radiation," *Terato., Carcino., and Muta.*, 16:219-27 (1996), discusses the effect of hydrogen peroxide and  $\gamma$ -radiation on DNA strand breaks in the presence of and in the absence of 3-aminobenzamide, a potent inhibitor of PARP. Cristovao et al. observed a PARP-dependent recovery of DNA strand breaks in leukocytes treated with hydrogen peroxide.

15

20 PARP inhibitors have been reported to be effective in radiosensitizing hypoxic tumor cells and effective in preventing tumor cells from recovering from potentially lethal damage of DNA after radiation therapy, presumably by their ability to prevent DNA repair. See U.S. Patent Nos. 5,032,617; 5,215,738; and 5,041,653.

25 Evidence also exists that PARP inhibitors are useful for treating inflammatory bowel disorders. Salzman et al., "Role of Peroxynitrite and Poly(ADP-Ribose) Synthase Activation Experimental Colitis," *Japanese J. Pharm.*, 75, Supp. I:15 (1997), discusses the ability of PARP inhibitors to prevent or treat colitis. Colitis was induced in rats by intraluminal administration of the hapten trinitrobenzene sulfonic acid in 50% ethanol. Treated rats received 3-aminobenzamide, a specific inhibitor of PARP activity. Inhibition of PARP

activity reduced the inflammatory response and restored the morphology and the energetic status of the distal colon. See also, Southan et al., "Spontaneous Rearrangement of Aminoalkylithioureas into Mercaptoalkylguanidines, a Novel 5 Class of Nitric Oxide Synthase Inhibitors with Selectivity Towards the Inducible Isoform", *Br. J. Pharm.*, 117:619-32 (1996); and Szabó et al., "Mercaptoethylguanidine and Guanidine Inhibitors of Nitric Oxide Synthase React with Peroxynitrite and Protect Against Peroxynitrite-induced Oxidative Damage", *J. 10 Biol. Chem.*, 272:9030-36 (1997).

Evidence also exists that PARP inhibitors are useful for treating arthritis. Szabó et al., "Protective Effects of an Inhibitor of Poly(ADP-Ribose) Synthetase in Collagen-Induced Arthritis," *Japanese J. Pharm.*, 75, Supp. I:102 (1997), 15 discusses the ability of PARP inhibitors to prevent or treat collagen-induced arthritis. See also Szabó et al., "DNA Strand Breakage, Activation of Poly(ADP-Ribose) Synthetase, and Cellular Energy Depletion are Involved in the Cytotoxicity in Macrophages and Smooth Muscle Cells Exposed to Peroxynitrite," 20 *Proc. Natl. Acad. Sci. USA*, 93:1753-58 (March 1996); Bauer et al., "Modification of Growth Related Enzymatic Pathways and Apparent Loss of Tumorigenicity of a ras-transformed Bovine Endothelial Cell Line by Treatment with 5-Iodo-6-amino-1,2-benzopyrone (INH<sub>2</sub>BP)", *Intl. J. Oncol.*, 8:239-52 (1996); and 25 Hughes et al., "Induction of T Helper Cell Hyporesponsiveness in an Experimental Model of Autoimmunity by Using Nonmitogenic Anti-CD3 Monoclonal Antibody", *J. Immuno.*, 153:3319-25 (1994).

Further, PARP inhibitors appear to be useful for treating diabetes. Heller et al., "Inactivation of the Poly(ADP-Ribose) Polymerase Gene Affects Oxygen Radical and Nitric Oxide Toxicity in Islet Cells," *J. Biol. Chem.*, 270:19, 11176-80 (May 1995), discusses the tendency of PARP to deplete cellular NAD+ and induce the death of insulin-producing islet cells. Heller et al. used cells from mice with inactivated PARP genes and

found that these mutant cells did not show NAD<sup>+</sup> depletion after exposure to DNA-damaging radicals. The mutant cells were also found to be more resistant to the toxicity of NO.

Further still, PARP inhibitors have been shown to be  
5 useful for treating endotoxic shock or septic shock. Zingarelli et al., "Protective Effects of Nicotinamide Against Nitric Oxide-Mediated Delayed Vascular Failure in Endotoxic Shock: Potential Involvement of PolyADP Ribosyl Synthetase," Shock, 5:258-64 (1996), suggests that inhibition of the DNA  
10 repair cycle triggered by poly(ADP ribose) synthetase has protective effects against vascular failure in endotoxic shock. Zingarelli et al. found that nicotinamide protects against delayed, NO-mediated vascular failure in endotoxic shock. Zingarelli et al. also found that the actions of nicotinamide  
15 may be related to inhibition of the NO-mediated activation of the energy-consuming DNA repair cycle, triggered by poly(ADP ribose) synthetase. See also, Cuzzocrea, "Role of Peroxynitrite and Activation of Poly(ADP-Ribose) Synthetase in the Vascular Failure Induced by Zymosan-activated Plasma,"  
20 Brit. J. Pharm., 122:493-503 (1997).

Yet another known use for PARP inhibitors is treating cancer. Suto et al., "Dihydroisoquinolinones: The Design and Synthesis of a New Series of Potent Inhibitors of Poly(ADP-Ribose) Polymerase", Anticancer Drug Des., 7:107-17 (1991),  
25 discloses processes for synthesizing a number of different PARP inhibitors. In addition, Suto et al., U.S. Patent No. 5,177,075, discusses several isoquinolines used for enhancing the lethal effects of ionizing radiation or chemotherapeutic agents on tumor cells. Weltin et al., "Effect of 6(5H)-  
30 Phenanthridinone, an Inhibitor of Poly(ADP-ribose) Polymerase, on Cultured Tumor Cells", Oncol. Res., 6:9, 399-403 (1994), discusses the inhibition of PARP activity, reduced proliferation of tumor cells, and a marked synergistic effect when tumor cells are co-treated with an alkylating drug.

Still another use for PARP inhibitors is the treatment of peripheral nerve injuries, and the resultant pathological pain syndrome known as neuropathic pain, such as that induced by chronic constriction injury (CCI) of the common sciatic nerve 5 and in which transsynaptic alteration of spinal cord dorsal horn characterized by hyperchromatosis of cytoplasm and nucleoplasm (so-called "dark" neurons) occurs. See Mao et al., Pain, 72:355-366 (1997).

PARP inhibitors have also been used to extend the lifespan 10 and proliferative capacity of cells including treatment of diseases such as skin aging, Alzheimer's disease, atherosclerosis, osteoarthritis, osteoporosis, muscular dystrophy, degenerative diseases of skeletal muscle involving replicative senescence, age-related macular degeneration, 15 immune senescence, AIDS, and other immune senescence diseases; and to alter gene expression of senescent cells. See WO 98/27975.

Large numbers of known PARP inhibitors have been described in Banasik et al., "Specific Inhibitors of Poly(ADP-Ribose) 20 Synthetase and Mono(ADP-Ribosyl)-Transferase", J. Biol. Chem., 267:3, 1569-75 (1992), and in Banasik et al., "Inhibitors and Activators of ADP-Ribosylation Reactions", Molec. Cell. Biochem., 138:185-97 (1994).

However, the approach of using these PARP inhibitors in 25 the ways discussed above has been limited in effect. For example, side effects have been observed with some of the best-known PARP inhibitors, as discussed in Milam et al., "Inhibitors of Poly(Adenosine Diphosphate-Ribose) Synthesis: Effect on Other Metabolic Processes", Science, 223:589-91 30 (1984). Specifically, the PARP inhibitors 3-aminobenzamide and benzamide not only inhibited the action of PARP but also were shown to affect cell viability, glucose metabolism, and DNA synthesis. Thus, it was concluded that the usefulness of these PARP inhibitors may be severely restricted by the difficulty of

finding a dose that will inhibit the enzyme without producing additional metabolic effects.

Accordingly, there remains a need for compounds that inhibit PARP activity, compositions containing those compounds and methods utilizing those compounds, wherein the compounds produce more potent and reliable effects with fewer side effects, with respect to inhibiting PARP activity and treating the diseases and conditions discussed herein.

Further, multicyclic thioalkyl compounds other than the compounds of the invention are known. 7,8,9,10-tetrahydro-6-(methylthio)-phenanthridine, which has the following structure:



is disclosed in Ried et al., "Reactions of Cyclic Enamines", *Chem. Abstracts*, 64:695e (1966).

15 2,3-dihydro-4-(methylthio)-1H-cyclopenta[c]-quinoline, which has the following structure:




is disclosed in Schoen et al., *Rocz. Chem.*, 41:1, 89-101 (1967).

20 However, it is not believed that these compounds have been shown to inhibit PARP activity.

#### SUMMARY OF THE INVENTION

The compounds of the invention have formula I:




or a pharmaceutically acceptable salt, hydrate, ester, solvate, prodrug, metabolite, stereoisomer, or mixtures thereof, wherein:

- 5      R<sup>1</sup> is lower alkyl, lower alkenyl or lower alkynyl;
- R<sup>9</sup>, when present, is hydrogen or lower alkyl;
- Y represents the atoms necessary to form a fused 5- to 6-membered ring that is aromatic or nonaromatic and carbocyclic or heterocyclic;
- 10     Z is (i) -CHR<sup>2</sup>CHR<sup>3</sup>- where R<sup>2</sup> and R<sup>3</sup> are independently hydrogen, alkyl, aryl or aralkyl;
- (ii) -R<sup>6</sup>C=CR<sup>3</sup>- where R<sup>6</sup> and R<sup>3</sup> are independently hydrogen, lower alkyl, aryl, aralkyl, chlorine, bromine or -NR<sup>7</sup>R<sup>8</sup>, where R<sup>7</sup> and R<sup>8</sup> are independently hydrogen or lower alkyl, or, R<sup>6</sup> and R<sup>3</sup>, taken together, form a fused 5- to 6-membered ring that is aromatic or nonaromatic and carbocyclic or heterocyclic;
- 15     (iii) -R<sup>2</sup>C=N-;
- (iv) -CR<sup>2</sup>(OH)-NR<sup>7</sup>-; or
- (v) -C(O)-NR<sup>7</sup>-;

provided that when R<sup>1</sup> is methyl, R<sup>9</sup> is absent, and R<sup>6</sup> and R<sup>3</sup> form a 6-membered, carbocyclic unsaturated ring, Y is aromatic and/or heterocyclic.


- 25     In another embodiment, a process for making the compound of formula I comprises the step of contacting an intermediate of formula II:



II

with R-X, wherein X is a bromo, chloro or iodo moiety and R is alkyl, alkenyl or alkynyl, and wherein Y, Z and R' are as defined in formula I.

5 In yet another embodiment, the pharmaceutical composition of the invention comprises a pharmaceutically acceptable carrier and a compound of formula I:




or a pharmaceutically acceptable salt, hydrate, ester, solvate, 10 prodrug, metabolite, stereoisomer, or mixtures thereof, wherein:

- R<sup>1</sup> is lower alkyl, lower alkenyl or lower alkynyl;
- R', when present, is hydrogen or lower alkyl;
- Y represents the atoms necessary to form a fused 5- to 6-membered ring that is aromatic or nonaromatic and carbocyclic or heterocyclic;
- Z is (i) -CHR<sup>2</sup>CHR<sup>3</sup>- where R<sup>2</sup> and R<sup>3</sup> are independently hydrogen, alkyl, aryl or aralkyl;
- (ii) -R<sup>6</sup>C=CR<sup>3</sup>- where R<sup>6</sup> and R<sup>3</sup> are independently hydrogen, lower alkyl, aryl, aralkyl, chlorine, bromine or -NR<sup>7</sup>R<sup>8</sup>, where R<sup>7</sup> and R<sup>8</sup> are independently hydrogen or lower alkyl, or, R<sup>6</sup> and R<sup>3</sup>, taken together, form a fused 5- to 6-membered ring that is aromatic or nonaromatic and carbocyclic or heterocyclic;
- (iii) -R<sup>2</sup>C=N-;
- (iv) -CR<sup>2</sup>(OH)-NR<sup>7</sup>-; or
- (v) -C(O)-NR<sup>7</sup>-;

provided that when R<sup>1</sup> is methyl, R<sup>9</sup> is absent, and R<sup>6</sup> and R<sup>3</sup> form a 6-membered, carbocyclic unsaturated ring, Y is aromatic and/or heterocyclic.

In a still further embodiment of the invention, the 5 pharmaceutical composition of the invention comprises a pharmaceutically acceptable carrier and a compound of formula I:



or a pharmaceutically acceptable salt, hydrate, ester, solvate, 10 prodrug, metabolite, stereoisomer, or mixtures thereof, and a pharmaceutically acceptable carrier, wherein the compound of formula I is present in an amount that is sufficient to inhibit PARP activity, to treat or prevent tissue damage resulting from cell damage or death due to necrosis or apoptosis, to effect a 15 neuronal activity not mediated by NMDA toxicity, to effect a neuronal activity mediated by NMDA toxicity, to treat neural tissue damage resulting from ischemia and reperfusion injury, neurological disorders and neurodegenerative diseases; to prevent or treat vascular stroke; to treat or prevent 20 cardiovascular disorders; to treat other conditions and/or disorders such as age-related macular degeneration, AIDS and other immune senescence diseases, arthritis, atherosclerosis, cachexia, cancer, degenerative diseases of skeletal muscle involving replicative senescence, diabetes, head trauma, immune 25 senescence, inflammatory bowel disorders (such as colitis and Crohn's disease), muscular dystrophy, osteoarthritis, osteoporosis, chronic and/or acute pain (such as neuropathic pain), renal failure, retinal ischemia, septic shock (such as endotoxic shock), and skin aging; to extend the lifespan and 30 proliferative capacity of cells; to alter gene expression of senescent cells; or to radiosensitize hypoxic tumor cells, and

wherein:

R<sup>1</sup> is lower alkyl, lower alkenyl or lower alkynyl;

R<sup>9</sup>, when present, is hydrogen or lower alkyl;

Y represents the atoms necessary to form a fused 5- to 6-membered ring that is aromatic or nonaromatic and carbocyclic or heterocyclic;

Z is (i) -CHR<sup>2</sup>CHR<sup>3</sup>- where R<sup>2</sup> and R<sup>3</sup> are independently hydrogen, alkyl, aryl or aralkyl;

(ii) -R<sup>6</sup>C=CR<sup>3</sup>- where R<sup>6</sup> and R<sup>3</sup> are independently hydrogen, lower alkyl, aryl, aralkyl, chlorine, bromine or -NR<sup>7</sup>R<sup>8</sup>, where R<sup>7</sup> and R<sup>8</sup> are independently hydrogen or lower alkyl, or, R<sup>6</sup> and R<sup>3</sup>, taken together, form a fused 5- to 6-membered ring that is aromatic or nonaromatic and carbocyclic or heterocyclic;

(iii) -R<sup>2</sup>C=N-;

(iv) -CR<sup>2</sup>(OH)-NR<sup>7</sup>-; or

(v) -C(O)-NR<sup>7</sup>-;

provided that when R<sup>1</sup> is methyl, R<sup>9</sup> is absent, and R<sup>6</sup> and R<sup>3</sup> form a 6-membered, carbocyclic unsaturated ring, Y is aromatic and/or heterocyclic.

In an additional embodiment, a method of inhibiting PARP activity comprises administering a compound of formula I, as described above for the pharmaceutical compositions of the invention. In yet further embodiments, the amount of the compound administered in the methods of the invention is sufficient for treating tissue damage resulting from cell damage or death due to necrosis or apoptosis, neural tissue damage resulting from ischemia and reperfusion injury, or neurological disorders and neurodegenerative diseases; to prevent or treat vascular stroke; to treat or prevent cardiovascular disorders; to treat other conditions and/or disorders such as age-related macular degeneration, AIDS and other immune senescence diseases, arthritis, atherosclerosis,

cachexia, cancer, degenerative diseases of skeletal muscle involving replicative senescence, diabetes, head trauma, immune senescence, inflammatory bowel disorders (such as colitis and Crohn's disease), muscular dystrophy, osteoarthritis, 5 osteoporosis, chronic and/or acute pain (such as neuropathic pain), renal failure, retinal ischemia, septic shock (such as endotoxic shock), and skin aging; to extend the lifespan and proliferative capacity of cells; to alter gene expression of senescent cells; or to radiosensitize hypoxic tumor cells.

10

#### BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 shows the distribution of the cross-sectional infarct area at representative levels along the rostrocaudal axis, as measured from the interaural line in non-treated 15 animals and in animals treated with 10 mg/kg of 3,4-dihydro-5-[4-(1-piperidinyl)-butoxy]-1(2H)-isoquinolinone.

Figure 2 shows the effect of intraperitoneal administration of 3,4-dihydro-5-[4-(1-piperidinyl)-butoxy]-1(2H)-isoquinolinone on the infarct volume.

20

#### DETAILED DESCRIPTION OF THE INVENTION

##### Thioalkyl Compounds

The thioalkyl compounds of the present invention preferably inhibit PARP activity. As such, they may treat or prevent neural tissue damage resulting from cell damage or death due to necrosis or apoptosis, cerebral ischemia and reperfusion injury or neurodegenerative diseases in an animal; they may extend the lifespan and proliferative capacity of cells and thus be used to treat or prevent diseases associated therewith; they may alter gene expression of senescent cells; and they may radiosensitize hypoxic tumor cells. Preferably, the compounds of the invention treat or prevent tissue damage resulting from cell damage or death due to necrosis or apoptosis, and/or effect neuronal activity, either mediated or

not mediated by NMDA toxicity. These compounds are thought to interfere with more than the glutamate neurotoxicity and NO-mediated biological pathways. Further, the compounds of the invention can treat or prevent other tissue damage related to  
5 PARP activation.

For example, the compounds of the invention can treat or prevent cardiovascular tissue damage resulting from cardiac ischemia or reperfusion injury. Reperfusion injury, for instance, occurs at the termination of cardiac bypass  
10 procedures or during cardiac arrest when the heart, once prevented from receiving blood, begins to reperfuse.

The compounds of the present invention can also be used to extend or increase the lifespan or proliferation of cells and thus to treat or prevent diseases associated therewith and  
15 induced or exacerbated by cellular senescence including skin aging, atherosclerosis, osteoarthritis, osteoporosis, muscular dystrophy, degenerative diseases of skeletal muscle involving replicative senescence, age-related macular degeneration, immune senescence, AIDS and other immune senescence diseases,  
20 and other diseases associated with cellular senescence and aging, as well as to alter the gene expression of senescent cells. These compounds can also be used to treat cancer and to radiosensitize hypoxic tumor cells to render the tumor cells more susceptible to radiation therapy and to prevent the tumor  
25 cells from recovering from potentially lethal damage of DNA after radiation therapy, presumably by their ability to prevent DNA repair. The compounds of the present invention can be used to prevent or treat vascular stroke; to treat or prevent cardiovascular disorders; to treat other conditions and/or  
30 disorders such as age-related macular degeneration, AIDS and other immune senescence diseases, arthritis, atherosclerosis, cachexia, cancer, degenerative diseases of skeletal muscle involving replicative senescence, diabetes, head trauma, immune senescence, inflammatory bowel disorders (such as colitis and


Crohn's disease), muscular dystrophy, osteoarthritis, osteoporosis, chronic and/or acute pain (such as neuropathic pain), renal failure, retinal ischemia, septic shock (such as endotoxic shock), and skin aging.

5       The inventors have now discovered that select thioalkyl compounds can inhibit PARP activity and can ameliorate tissue damage resulting from cell damage or death due to necrosis or apoptosis and/or neural tissue damage, including that following focal ischemia and reperfusion injury; can increase or extend  
10 the lifespan or proliferation of cells; can alter gene expression in senescent cells; and can radiosensitize tumor cells. Generally, inhibition of PARP activity spares the cell from energy loss, preventing irreversible depolarization of the neurons and, thus, provides neuroprotection. While not wishing  
15 to be bound thereby, it is thought that PARP activation may play a common role in still other excitotoxic mechanisms, perhaps as yet undiscovered, in addition to the production of free radicals and NO. Since PARP is necessary for DNA repair, the inhibition of PARP can also be used to prevent radiation  
20 damaged tumor cells from recovering from potentially lethal damage of DNA by preventing DNA repair. PARP inhibitors may also be used to extend or increase the lifespan and proliferation of cells and to thus prevent or treat diseases and conditions associated with cellular senescence, and can be  
25 used to alter the gene expression of senescent cells. can increase or extend the lifespan or proliferation of cells; can alter gene expression in senescent cells; and can radiosensitize tumor cells..

      The thioalkyl compounds of the invention act as PARP  
30 inhibitors to treat or prevent tissue damage resulting from cell damage or death due to necrosis or apoptosis and/or neural tissue damage resulting from cerebral ischemia and reperfusion injury or neurodegenerative diseases in an animal; to extend and increase the lifespan and proliferative capacity of cells;

to alter gene expression of senescent cell; and to radiosensitize tumor cells. These compounds are thought to interfere with more than the NMDA-neurotoxicity and NO-mediated biological pathways. Preferably, the compounds of the 5 invention exhibit an IC<sub>50</sub> for inhibiting PARP in vitro of about 100 μM or lower, more preferably, about 25 μM or lower.


The compound of the invention has formula I:



or a pharmaceutically acceptable salt, hydrate, ester, solvate, 10 prodrug, metabolite, stereoisomer, or mixtures thereof, wherein Y represents the atoms necessary to form a fused 5-to 6-membered ring that is aromatic or nonaromatic and carbocyclic or heterocyclic.

When Y forms a fused 5-membered carbocyclic ring, examples 15 of Y include such rings as a fused cyclopentane, cyclopentene, cyclopentadiene and the like. When Y forms a 5-membered heterocyclic ring, Y can be, for example, a fused pyrrole, isopyrrole, imidazole, isoimidazole, pyrazole, pyrrolidine, pyrrolidine, imidazolidine, imidazoline, pyrazolidine, 20 pyrazoline, isothiazole, isoxazole, furazan, thiophene, 1,2,3-triazole, 1,2,4-triazole, dithiole, oxathiole, oxazole, thiazole, isothiazole, oxadiazole, oxathiazole, dioxazole, oxathiazole and the like ring structures.

When Y forms a fused 6-membered carbocyclic ring, examples 25 of useful Y groups include such rings as a fused cyclohexane, cyclohexene, benzene and like nuclei, optionally substituted with additional fused rings forming, for example, naphthalene, anthracene, phenanthrene, benzonaphthene and like ring systems. When Y forms a 6-membered heterocyclic ring, examples include 30 a pyridine, pyrazine, pyrimidine, pyridazine, pyran, pyrone, dioxin, piperidine, piperazine, morpholine, triazene, oxazine,

**isoxazine, oxathiazine, oxadiazine and the like rings**


Crohn's disease), muscular dystrophy, osteoarthritis, osteoporosis, chronic and/or acute pain (such as neuropathic pain), renal failure, retinal ischemia, septic shock (such as endotoxic shock), and skin aging.

5       The inventors have now discovered that select thioalkyl compounds can inhibit PARP activity and can ameliorate tissue damage resulting from cell damage or death due to necrosis or apoptosis and/or neural tissue damage, including that following focal ischemia and reperfusion injury; can increase or extend  
10      the lifespan or proliferation of cells; can alter gene expression in senescent cells; and can radiosensitize tumor cells. Generally, inhibition of PARP activity spares the cell from energy loss, preventing irreversible depolarization of the neurons and, thus, provides neuroprotection. While not wishing  
15      to be bound thereby, it is thought that PARP activation may play a common role in still other excitotoxic mechanisms, perhaps as yet undiscovered, in addition to the production of free radicals and NO. Since PARP is necessary for DNA repair, the inhibition of PARP can also be used to prevent radiation  
20      damaged tumor cells from recovering from potentially lethal damage of DNA by preventing DNA repair. PARP inhibitors may also be used to extend or increase the lifespan and proliferation of cells and to thus prevent or treat diseases and conditions associated with cellular senescence, and can be  
25      used to alter the gene expression of senescent cells. can increase or extend the lifespan or proliferation of cells; can alter gene expression in senescent cells; and can radiosensitize tumor cells..

30      The thioalkyl compounds of the invention act as PARP inhibitors to treat or prevent tissue damage resulting from cell damage or death due to necrosis or apoptosis and/or neural tissue damage resulting from cerebral ischemia and reperfusion injury or neurodegenerative diseases in an animal; to extend and increase the lifespan and proliferative capacity of cells;

to alter gene expression of senescent cell; and to radiosensitize tumor cells. These compounds are thought to interfere with more than the NMDA-neurotoxicity and NO-mediated biological pathways. Preferably, the compounds of the 5 invention exhibit an IC<sub>50</sub> for inhibiting PARP in vitro of about 100 μM or lower, more preferably, about 25 μM or lower.

The compound of the invention has formula I:



or a pharmaceutically acceptable salt, hydrate, ester, solvate, 10 prodrug, metabolite, stereoisomer, or mixtures thereof, wherein Y represents the atoms necessary to form a fused 5-to 6-membered ring that is aromatic or nonaromatic and carbocyclic or heterocyclic.

When Y forms a fused 5-membered carbocyclic ring, examples 15 of Y include such rings as a fused cyclopentane, cyclopentene, cyclopentadiene and the like. When Y forms a 5-membered heterocyclic ring, Y can be, for example, a fused pyrrole, isopyrrole, imidazole, isoimidazole, pyrazole, pyrrolidine, pyrroline, imidazolidine, imidazoline, pyrazolidine, 20 pyrazoline, isothiazole, isoxazole, furazan, thiophene, 1,2,3-triazole, 1,2,4-triazole, dithiole, oxathiole, oxazole, thiazole, isothiazole, oxadiazole, oxathiazole, dioxazole, oxathiazole and the like ring structures.

When Y forms a fused 6-membered carbocyclic ring, examples 25 of useful Y groups include such rings as a fused cyclohexane, cyclohexene, benzene and like nuclei, optionally substituted with additional fused rings forming, for example, naphthalene, anthracene, phenanthrene, benzonaphthene and like ring systems. When Y forms a 6-membered heterocyclic ring, examples include 30 a pyridine, pyrazine, pyrimidine, pyridazine, pyran, pyrone, dioxin, piperidine, piperazine, morpholine, triazene, oxazine,

isoxazine, oxathiazine, oxadiazine, and the like rings.

Y may be aromatic, such as pyrrole, benzene or pyridine; or non-aromatic such as cyclopentene, piperidyl or piperazinyl.


Y may be unsubstituted or substituted with one or more  
5 non-interfering substituents. For example, Y may be substituted with an alkyl group such as methyl, ethyl, propyl, butyl, pentyl, hexyl, isopropyl, isobutyl, tert-butyl, n-pentyl, 2-methylpentyl, 2-methylhexyl, dodecyl, octadecyl and the like; with an alkenyl group such as ethenyl, propenyl,  
10 butenyl, pentenyl, 2-methylpentenyl, vinyl, isopropenyl, 2,2-dimethyl-1-propenyl, decenyl, hexadecenyl and the like; with an alkynyl group such as ethynyl, propynyl, butynyl, pentynyl, hexynyl, heptynyl, octynyl and the like; with an alkanoyl group such as formyl, acetyl, propanoyl, butanoyl, pentanoyl, benzoyl  
15 and the like; with a cycloalkyl group such as adamantyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctanyl, cyclononyl, cyclodecyl and the like; with a cycloalkenyl group such as cyclopropenyl, cyclopentadienyl, cyclohexenyl, cyclooctenyl and the like; with an aralkyl group such as  
20 benzyl, 3-(1)-naphthyl-1-propyl, p-halobenzyl, p-ethylbenzyl, 1-phenyl-1-propyl, 3-pyridinyl-1-propyl, 1-phenyl-2-sec-butyl, 4-phenyl-4-methyl-1-pentyl and the like; or with an aryl group such as phenyl, naphthyl, pyridinyl, thienyl and the like.

"Aryl" is defined as an unsaturated carbocyclic or  
25 heterocyclic moiety which may be either unsubstituted or substituted with one or more non-interfering substituent(s). Examples include, without limitation, phenyl, benzyl, naphthyl, indenyl, azulenyl, fluorenyl, anthracenyl, indolyl, isoindolyl, indolinyl, benzofuranyl, benzothiophenyl, indazolyl,  
30 benzimidazolyl, benzithiazolyl, tetrahydrofuranayl, tetrahydropyranyl, pyridyl, pyrrolyl, pyrrolidinyl, pyridinyl, pyrimidinyl, purinyl, quinolinyl, isoquinolinyl, tetrahydroquinolinyl, quinolizinyl, furyl, thiophenyl, imidazolyl, oxazolyl, benzoxazolyl, thiazolyl, isoxazolyl,


isotriazolyl, oxadiazolyl, triazolyl, thiadiazolyl, pyridazinyl, pyrimidinyl, pyrazolyl, pyrazolinyl, pyrazolidinyl, thienyl, tetrahydroisoquinolinyl, cinnolinyl, phthalazinyl, quinazolinyl, quinoxalinyl, naphthyridinyl, 5 pteridinyl, carbozolyl, acridinyl, phenazinyl, phenothiazinyl, phenoxazinyl and the like.

Possible substituents on an aryl group can be any non-interfering substituent. However, preferred substituents include, without limitation, alkyl, alkenyl, alkoxy, phenoxy, 10 benzyloxy, cycloalkyl, cycloalkenyl, hydroxy, carboxy, carbonyl, amino, amido, cyano, isocyano, nitro, nitroso, nitrilo, isonitrilo, imino, azo, diazo, sulfonyl, sulfoxy, thio, thiocarbonyl, sulfhydryl, halo, haloalkyl, trifluoromethyl and aryl.

15 Y may also be substituted with one or more of the following structures:



Specific examples of particularly useful Y structures are shown below:



In a preferred embodiment, however, Y has at least one site of unsaturation. Even more preferably, Y represents the atoms necessary to form a fused benzene ring.

5 R<sup>1</sup> may be lower alkyl, lower alkenyl or lower alkynyl.  
"Lower alkyl" and "lower alkenyl" respectively include  
cycloalkyl and cycloalkenyl. Examples of useful alkyl,  
alkenyl, alkynyl, cycloalkyl and cycloalkenyl groups are shown  
above. R<sup>1</sup> may itself be unsubstituted or substituted with one  
10 or more additional alkyl, alkenyl, alkynyl, lower alkanoyl,  
aralkyl or aryl groups, examples of which are shown above.

Z in formula I can be (i)  $-\text{CHR}^2\text{CHR}^3-$ ;  
 (ii)  $-\text{R}^6\text{C}=\text{CR}^3-$ ;  
 (iii)  $-\text{R}^2\text{C}=\text{N}-$ ;  
 15 (iv)  $-\text{CR}^2(\text{OH})-\text{NR}^7-$ ; or  
 (v)  $-\text{C}(\text{O})-\text{NR}^7-$ .

Preferably, Z is  $-\text{CHR}^2\text{CHR}^3-$ ,  $-\text{R}^6\text{C}=\text{CR}^3-$  or  $-\text{R}^2\text{C}=\text{N}-$ .

R<sup>2</sup> and R<sup>3</sup> in formulas (i) - (v) above can be, independently, hydrogen; alkyl, such as methyl, ethyl, 20 isopropyl, tert-butyl, n-pentyl, sec-octyl, dodecyl and the

like; phenyl; or benzyl.

In formula (ii) ( $-R^6C=CR^3-$ ),  $R^6$  and  $R^3$ , independently can be hydrogen, alkyl as described above, phenyl, benzyl, chlorine, bromine,  $-NO_2$ ,  $-COOH$ ,  $-COOCH_3$ , or  $-NR^7R^8$ . When  $R_3$  is  $-NR^7R^8$ ,  $R^8$  5 is independently hydrogen or lower alkyl as described above.


Alternatively,  $R^3$  and  $R^6$ , taken together, can form a fused aromatic or non-aromatic, mono-, bi- or tricyclic, carbocyclic or heterocyclic ring, wherein each individual ring has 5-6 ring member atoms. Examples of such rings include a fused 10 cyclopentadiene, pyrrole, isopyrrole, imidazole, isoimidazole, triazole, pyrazole, pyridine, thiophene, furan, thiazole, isothiazole, oxazole, isoxazole, oxadiazole, benzene, naphthalene, acridine, cyclohexane, cyclohexene, indole, pyran, pyrone, pyridine, pyrazine, pyrimidine, pyridazine, or triazine 15 nucleus. When Z is  $-R^6C=CR^3-$  and forms a fused aromatic or non-aromatic ring, the ring formed may be substituted with one or more non-hydrogen non-interfering substituents.

Possible substituents of Y, or of the fused ring formed when Z is  $-R^6C=CR^3-$ , include any substituent that does not 20 interfere with the reactions and purposes of the invention. Examples include, without limitation,  $C_1-C_6$  straight or branched chain alkyl,  $C_2-C_6$  straight or branched chain alkenyl,  $C_1-C_6$  alkoxy,  $C_2-C_6$  alkenyloxy, phenoxy, benzyloxy,  $C_3-C_8$  cycloalkyl,  $C_5-C_6$  cycloalkenyl, hydroxy, carboxy, carbonyl, amino, amido, 25 cyano, isocyano, nitro, nitroso, nitrilo, isonitrilo, imino, azo, diazo, sulfonyl, sulfoxy, thio, thiocarbonyl, sulfhydryl, halo, haloalkyl, trifluoro-methyl, carbocyclic and heterocyclic moieties. Carbocyclic moieties include alicyclic and aromatic structures.


30 Preferably, however, Z is  $-R^6C=CR^3-$ , forms a fused aromatic ring, and neither Y nor Z is substituted with a non-hydrogen substituent.

In the compound of the invention, the multicyclic nuclear ring structure formed with Z and the fused ring Y is preferably


one of the following:




isoquinoline




phthalazine




pteridine




quinazoline




pyrido[3,4-b]pyridine




pyrido[4,3-b]pyridine



pyrazino[3,d]pyridazine



purine



phenanthridine


5

or a pharmaceutically acceptable salt, hydrate, ester, solvate, prodrug, metabolite, stereoisomer, or mixtures thereof. More preferably, the compound has an isoquinoline, a phenanthridine, a phthalazine, or a quinazoline nucleus. Even more preferably,

10 the compound has an isoquinoline nucleus.

Specific examples of useful compounds are shown below in

Table I:

TABLE I

5









10





15

$R^1$	Y	Z
-CH <sub>3</sub>		-CH <sub>2</sub> -CH <sub>2</sub> -
-CH <sub>3</sub>		-CH-CH <sub>2</sub> -   CH <sub>3</sub>
-CH <sub>2</sub> CH <sub>3</sub>		-CH-CH <sub>2</sub> -   C <sub>6</sub> H <sub>5</sub>
-CH <sub>2</sub> CH <sub>2</sub> CH <sub>3</sub>		-CH-CH <sub>2</sub> -   CH <sub>2</sub> -C <sub>6</sub> H <sub>5</sub>
-CH <sub>2</sub> CH <sub>2</sub> CH <sub>2</sub> CH <sub>3</sub>		- CH - CH <sub>2</sub> -   CH / \ CH <sub>3</sub> CH <sub>3</sub>
-CH <sub>3</sub>		- CH - CH <sub>2</sub> -   CH <sub>3</sub> -C-CH <sub>3</sub>   CH <sub>3</sub>

$R^1$	$Y$	$Z$
$-CH_2CH_3$		$-C=CH-$   $C_2H_5$
$-CH_2CH_2CH_3$		$-C=CH-$   $C_6H_5$
5 $-CH_2CH_2CH_2CH_3$		$-C=CH-$   $CH_2-C_6H_5$
$-CH_3$		$-CH_2-CH_2-$
$-CH_3$		$-CH-CH_2-$   $CH_3$
$-CH_2CH_3$		$-CH-CH_2-$   $C_6H_5$
10 $-CH=CH_2$		$-C=CH-$   $Cl$
15 $-CH_2CH_2CH=CH_2$		$-C=CH-$   $Br$

<b>R<sup>1</sup></b>	<b>Y</b>	<b>Z</b>
-CH <sub>2</sub> CH=CHPh		$\begin{array}{c} -\text{C}=\text{CH}- \\   \\ \text{NH}-\text{C}_2\text{H}_5 \end{array}$
-C≡CH		$-\text{CH}_2=\text{N}-$
5 -CH <sub>2</sub> CH <sub>2</sub> CH=CHCH <sub>2</sub> Ph		$\begin{array}{c} -\text{C}=\text{N}- \\   \\ \text{CH} \\ \diagup \quad \diagdown \\ \text{CH}_3 \quad \text{CH}_3 \end{array}$
10 -CH <sub>2</sub> CHPhCH(CH <sub>3</sub> ) <sub>2</sub>		$\begin{array}{c} -\text{CH}-\text{NH}- \\   \\ \text{OH} \end{array}$
-CH <sub>3</sub>		$\begin{array}{c} \text{CH}_3 \quad \text{CH}_3 \\   \quad   \\ -\text{C}-\text{N}- \\   \\ \text{OH} \end{array}$
15 -CH <sub>2</sub> CH <sub>3</sub>		$-\text{CO}-\text{NH}-$
-CH <sub>2</sub> CH <sub>2</sub> CH <sub>3</sub>		$\begin{array}{c} -\text{CO}-\text{NH}- \\   \\ \text{C}_2\text{H}_5 \end{array}$


<b>R<sup>1</sup></b>	<b>Y</b>	<b>Z</b>
-CH <sub>2</sub> CH <sub>2</sub> CH <sub>2</sub> CH <sub>3</sub>		
-CH=CH <sub>2</sub>		
5 -CH <sub>2</sub> CH <sub>2</sub> CH=CH <sub>2</sub>		
-CH <sub>2</sub> CH <sub>2</sub> CH <sub>2</sub> CH <sub>2</sub> CH <sub>2</sub> CH <sub>3</sub>		-CH <sub>2</sub> -CH <sub>2</sub> -
10 -CH <sub>2</sub> CH <sub>2</sub> CH <sub>2</sub> C≡CH		-CH <sub>2</sub> -CH <sub>2</sub> -
15 -CH <sub>2</sub> CH <sub>2</sub> CH=CHCH <sub>2</sub> Ph		-CH <sub>2</sub> -CH <sub>2</sub> -

$R^1$	$Y$	$Z$
$-CH_2CHPhCH(CH_3)_2$		$-CH_2-CH_2-$
$-CH_3$		$-CH_2-CH_2-$
5 $-CH_2CH_3$		$-CH-CH_2-$   CH <sub>3</sub>
$-CH_2CH_2CH_3$		$-CH-CH_2-$   C <sub>6</sub> H <sub>5</sub>
10 $-CH_2CH_2CH_2CH_3$		$-CH-CH_2-$   CH <sub>2</sub> -C <sub>6</sub> H <sub>5</sub>
$-CH_2CH_2CH_2CH_2CH_3$		$-CH-CH_2-$   CH / \ / \ / \ / CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub>
$-CH_2CH(CH_3)_2$		$-CH-CH_2-$   CH <sub>3</sub> -C-CH <sub>3</sub>   CH <sub>3</sub>
15 $-CH=CH_2$		$-C=CH-$   C <sub>2</sub> H <sub>5</sub>

$R^1$	$Y$	$Z$
- $\text{CH}_2\text{CH}_2\text{CH}=\text{CHCH}_2\text{CH}=\text{C}$ $\text{H}_2$		- $\text{C} = \text{CH}$ -   $\text{C}_6\text{H}_5$
5 - $\text{CH}_3$		- $\text{C} = \text{CH}$ -   $\text{CH}_2-\text{C}_6\text{H}_5$
- $\text{CH}_2\text{CH}_2\text{CH}=\text{CHCH}_2\text{Ph}$		- $\text{C} = \text{CH}$ -   $\text{Cl}$
10 - $\text{CH}_2\text{CH}_2\text{CH}_2\text{CH}_2\text{CH}_2\text{CH}_3$		- $\text{C} = \text{CH}$ -   $\text{Br}$
- $\text{CH}_3$		- $\text{C} = \text{CH}$ -   $\text{NH-C}_2\text{H}_5$
- $\text{CH}_2\text{CH}_3$		- $\text{CH}_2 = \text{N}$ -
15 - $\text{CH}_2\text{CH}_2\text{CH}_3$		- $\text{C} = \text{N}$ -   CH / \ \/ CH <sub>3</sub> CH <sub>3</sub>
20 - $\text{CH}_2\text{CH}_2\text{CH}_2\text{CH}_3$		- $\text{CH-NH}$ -   $\text{OH}$

$R^1$	$Y$	$Z$
$-CH_2CH_2CH_2CH_2CH_3$		$\begin{array}{c} CH_3 \quad CH_3 \\   \qquad   \\ - C - N - \\   \\ OH \end{array}$
$-CH_2CH_2CH_2CH_2CH_3$		$-CO-NH-$
5 $\begin{array}{c} - \\ CH_2CH=CHCH_2CH_2CH_2P \\ h \end{array}$		$\begin{array}{c} -CO-NH- \\   \\ C_2H_5 \end{array}$
10 $-CH_2-COCH_3$		
$-CH_2-COCH_2CH_2CH_3$		
15 $\begin{array}{c} - \\ CH_2-C_6H_{11} \end{array}$		
$\begin{array}{c} - \\ CH_2CH=C(CH_2CH_2CH_3)_2 \end{array}$		$-CH_2-CH_2-$

<b>R<sup>1</sup></b>	<b>Y</b>	<b>Z</b>
-CH=CH-C <sub>7</sub> H <sub>13</sub>		-CH <sub>2</sub> -CH <sub>2</sub> -
5 -CH <sub>2</sub> -C <sub>4</sub> H <sub>7</sub>		-CH <sub>2</sub> -CH <sub>2</sub> -
-CH <sub>2</sub> CH <sub>2</sub> CH=CH-C <sub>5</sub> H <sub>9</sub>		-CH <sub>2</sub> -CH <sub>2</sub> -
-CH <sub>3</sub>		-CH <sub>2</sub> -CH <sub>2</sub> -
-CH <sub>3</sub>		-CH=CH-
10 -CH <sub>3</sub>		-CH <sub>2</sub> -CH <sub>2</sub> -




$R^1$	$Y$	$Z$
$-CH_3$		$-CH=CH-$

Also included are the pharmaceutically acceptable base or acid  
 5 addition salts, hydrates, esters, solvates, prodrugs,  
 metabolites, stereoisomers or mixtures thereof.


Preferred embodiments of the compound of formula I include  
 the following:



10

**I****II****III****IV**

The most preferred embodiment is embodiment III:



The compounds of the invention may be useful in a free base form, in the form of pharmaceutically acceptable salts, 5 pharmaceutically acceptable hydrates, pharmaceutically acceptable esters, pharmaceutically acceptable solvates, pharmaceutically acceptable prodrugs, pharmaceutically acceptable metabolites, and in the form of pharmaceutically acceptable stereoisomers. These forms are all within the scope 10 of the invention. In practice, the use of these forms amounts to use of the neutral compound.

"Pharmaceutically acceptable salt", "hydrate", "ester" or "solvate" refers to a salt, hydrate, ester, or solvate of the inventive compounds which possesses the desired pharmacological 15 activity and which is neither biologically nor otherwise undesirable. Organic acids can be used to produce salts, hydrates, esters, or solvates such as acetate, adipate, alginic acid, aspartate, benzoate, benzenesulfonate, p-toluenesulfonate, bisulfate, sulfamate, sulfate, naphthylate, 20 butyrate, citrate, camphorate, camphorsulfonate, cyclopentane-propionate, digluconate, dodecylsulfate, ethanesulfonate, fumarate, glucoheptanoate, glycerophosphate, hemisulfate heptanoate, hexanoate, 2-hydroxyethanesulfonate, lactate, maleate, methanesulfonate, 2-naphthalenesulfonate, nicotinate, 25 oxalate, tosylate and undecanoate. Inorganic acids can be used to produce salts, hydrates, esters, or solvates such as hydrochloride, hydrobromide, hydroiodide, and thiocyanate.

Examples of suitable base salts, hydrates, esters, or

solvates include hydroxides, carbonates, and bicarbonates of ammonia, alkali metal salts such as sodium, lithium and potassium salts, alkaline earth metal salts such as calcium and magnesium salts, aluminum salts, and zinc salts.

5        Salts, hydrates, esters, or solvates may also be formed with organic bases. Organic bases suitable for the formation of pharmaceutically acceptable base addition salts, hydrates, esters, or solvates of the compounds of the present invention include those that are non-toxic and strong enough to form such  
10      salts, hydrates, esters, or solvates. For purposes of illustration, the class of such organic bases may include mono-, di-, and trialkylamines, such as methylamine, dimethylamine, triethylamine and dicyclohexylamine; mono-, di- or trihydroxyalkylamines, such as mono-, di-, and triethanolamine;  
15      amino acids, such as arginine and lysine; guanidine; N-methyl-glucosamine; N-methyl-glucamine; L-glutamine; N-methyl-piperazine; morpholine; ethylenediamine; N-benzyl-phenethylamine; (trihydroxy-methyl)aminoethane; and the like. See, for example, "Pharmaceutical Salts," *J. Pharm. Sci.*,  
20      66:1, 1-19 (1977). Accordingly, basic nitrogen-containing groups can be quaternized with agents including: lower alkyl halides such as methyl, ethyl, propyl, and butyl chlorides, bromides and iodides; dialkyl sulfates such as dimethyl, diethyl, dibutyl and diethyl sulfates; long chain halides such  
25      as decyl, lauryl, myristyl and stearyl chlorides, bromides and iodides; and aralkyl halides such as benzyl and phenethyl bromides.

The acid addition salts, hydrates, esters, or solvates of the basic compounds may be prepared either by dissolving the free base of a PARP inhibitor in an aqueous or an aqueous alcohol solution or other suitable solvent containing the appropriate acid or base, and isolating the salt by evaporating the solution. Alternatively, the free base of the PARP inhibitor may be reacted with an acid, as well as reacting the

PARP inhibitor having an acid group thereon with a base, such that the reactions are in an organic solvent, in which case the salt separates directly or can be obtained by concentrating the solution.

5 "Pharmaceutically acceptable prodrug" refers to a derivative of the inventive compounds which undergoes biotransformation prior to exhibiting its pharmacological effect(s). The prodrug is formulated with the objective(s) of improved chemical stability, improved patient acceptance and  
10 compliance, improved bioavailability, prolonged duration of action, improved organ selectivity, improved formulation (e.g., increased hydrosolubility), and/or decreased side effects (e.g., toxicity). The prodrug can be readily prepared from the inventive compounds using methods known in the art, such as  
15 those described by *Burger's Medicinal Chemistry and Drug Chemistry*, Fifth Ed., Vol. 1, pp. 172-178, 949-982 (1995). For example, the inventive compounds can be transformed into prodrugs by converting one or more of the hydroxy or carboxy groups into esters.

20 "Pharmaceutically acceptable metabolite" refers to drugs that have undergone a metabolic transformation. After entry into the body, most drugs are substrates for chemical reactions that may change their physical properties and biologic effects. These metabolic conversions, which usually affect the polarity  
25 of the compound, alter the way in which drugs are distributed in and excreted from the body. However, in some cases, metabolism of a drug is required for therapeutic effect. For example, anticancer drugs of the antimetabolite class must be converted to their active forms after they have been  
30 transported into a cancer cell. Since most drugs undergo metabolic transformation of some kind, the biochemical reactions that play a role in drug metabolism may be numerous and diverse. The main site of drug metabolism is the liver, although other tissues may also participate.

A feature characteristic of many of these transformations is that the metabolic products are more polar than the parent drugs, although a polar drug does sometimes yield a less polar product. Substances with high lipid/water partition coefficients, which pass easily across membranes, also diffuse back readily from tubular urine through the renal tubular cells into the plasma. Thus, such substances tend to have a low renal clearance and a long persistence in the body. If a drug is metabolized to a more polar compound, one with a lower partition coefficient, its tubular reabsorption will be greatly reduced. Moreover, the specific secretory mechanisms for anions and cations in the proximal renal tubules and in the parenchymal liver cells operate upon highly polar substances.

As a specific example, phenacetin (acetophenetidin) and acetanilide are both mild analgesic and antipyretic agents, but are each transformed within the body to a more polar and more effective metabolite, p-hydroxyacetanilid (acetaminophen), which is widely used today. When a dose of acetanilid is given to a person, the successive metabolites peak and decay in the plasma sequentially. During the first hour, acetanilid is the principal plasma component. In the second hour, as the acetanilid level falls, the metabolite acetaminophen concentration reaches a peak. Finally, after a few hours, the principal plasma component is a further metabolite that is inert and can be excreted from the body. Thus, the plasma concentrations of one or more metabolites, as well as the drug itself; can be pharmacologically important.

The reactions involved in drug metabolism are often classified into two groups, as shown in the Table II. Phase I (or functionalization) reactions generally consist of (1) oxidative and reductive reactions that alter and create new functional groups and (2) hydrolytic reactions that cleave esters and amides to release masked functional groups. These changes are usually in the direction of increased polarity.

Phase II reactions are conjugation reactions in which the drug, or often a metabolite of the drug, is coupled to an endogenous substrate, such as glucuronic acid, acetic acid, or sulfuric acid.

5

TABLE II

Phase I Reactions (functionalization reactions):

(1) Oxidation via the hepatic microsomal P450 system:

- Aliphatic oxidation
- 10 Aromatic hydroxylation
- N-Dealkylation
- O-Dealkylation
- S-Dealkylation
- Epoxidation
- 15 Oxidative deamination
- Sulfoxide formation
- Desulfuration
- N-Oxidation and N-hydroxylation
- Dehalogenation

20 (2) Oxidation via nonmicrosomal mechanisms:

- Alcohol and aldehyde oxidation
- Purine oxidation
- Oxidative deamination (monoamine oxidase and diamine oxidase)

25 (3) Reduction:

- Azo and nitro reduction

(4) Hydrolysis:

- Ester and amide hydrolysis
- Peptide bond hydrolysis
- 30 Epoxide hydration

Phase II Reactions (conjugation reactions):

- (1) Glucuronidation
- (2) Acetylation

- (3) Mercapturic acid formation
- (4) Sulfate conjugation
- (5) N-, O-, and S-methylation
- (6) Trans-sulfuration

5

The compounds of the present invention possess one or more asymmetric center(s) and thus can be produced as mixtures (racemic and non-racemic) of stereoisomers, or as individual R- and S-stereoisomers. The individual stereoisomers may be 10 obtained by using an optically active starting material, by resolving a racemic or non-racemic mixture of an intermediate at some appropriate stage of synthesis, or by resolving a compound of formula I.

The term "isomers" refer to compounds having the same 15 number and kind of atoms, and hence, the same molecular weight, but differing in respect to the arrangement or configuration of the atoms. "Stereoisomers" are isomers that differ only in the arrangement of atoms in space. "Enantiomers" are a pair of stereoisomers that are non-superimposable mirror images of each 20 other.

"Diastereoisomers" are stereoisomers which are not mirror images of each other. "Racemic mixture" means a mixture containing equal, or roughly equal, parts of individual enantiomers. A "non-racemic mixture" is a mixture containing 25 unequal, or substantially unequal, parts of individual enantiomers or stereoisomers.

#### Synthesis of Compounds


Many non-thioalkyl PARP inhibitors can be synthesized by 30 known methods from starting materials that are known, are themselves commercially available, or may be prepared by methods used to prepare corresponding compounds in the literature. See, for example, Suto et al., "Dihydro-isocoumarinones: The Design and Synthesis of a New Series of

*Potent Inhibitors of Poly(ADP-ribose) Polymerase", Anticancer Drug Des., 6:107-17 (1991), which discloses processes for synthesizing a number of different PARP inhibitors.*


The usual building blocks for synthesizing organosulfur compounds are alkyl thiols, sometimes called mercaptans, which can be handled much like alcohols. Specifically, the thioalkyl compounds of the invention may be prepared through nucleophilic or radical reactions, such as:




10 Although direct nucleophilic displacements do not usually occur on simple aryl halides, the reaction to form a thioalkyl compound proceeds readily, for example:



15 Another synthetic pathway is to form a cyclic thiol, and then use the free-radical addition of an alkene to the thiol to form the thioalkyl compound of the invention, as shown below:




20 Thiols themselves can be readily prepared by the action of sulfur on Grignard reagents or by the hydrolysis of thiol esters, shown below:



A preferred synthetic pathway for preparing the compound of formula I comprises the step of contacting an intermediate


of formula II:



II

with R-X, wherein X is a chloro, bromo or iodo moiety; R is alkyl, alkenyl or alkynyl; and wherein Y, Z and R' are as described above for formula I.


An intermediate of formula II may be prepared by contacting an intermediate having formula III:



III

with Lawesson's reagent [otherwise known as 2,4-bis(4-methoxyphenyl)-1,3-dithia-2,4-diphosphetane-2,4-disulfide], P<sub>2</sub>S<sub>5</sub> or a reagent with similar activity. The above-described step can take place at varying temperatures depending, for example, upon the solvent used, the solubility of the intermediate of formula III in the solvent being used, and the susceptibility of the reactions to oxidize or participate in side reactions. Preferably, however, when the above reaction is used, it takes place at a temperature from about 10°C to about 70°C, preferably at about 50°C.

An intermediate of formula III may be prepared by contacting an intermediate having formula IV:



IV

with a Lewis base, such as ethanol, diethyl ether, hydroxide

ion, ammonia or water. Preferably, the Lewis base is ethanol.

An intermediate of formula IV may be prepared by contacting an intermediate having formula V:




V

5 with the hydroxide of a Group I element, such as KOH, to initiate a fusion reaction, for example, KOH fusion.

An intermediate of formula V can be prepared by methods known in the art. See L. Paquette, *Principles of Modern Heterocyclic Chemistry* 273-307 (1968).

10 The following scheme is intended as an illustration of the preparation of a preferred embodiment of the invention, and no limitation of the invention is implied.



15 The product, a compound of formula I, is isolated from the reaction mixture by conventional techniques, such as by

precipitating out, extraction with an immiscible solvent under appropriate pH conditions, evaporation, filtration, crystallization, or by column chromatography on silica gel and the like. Typically, however, the product is removed by either 5 crystallization or column chromatography on silica gel.

Other variations and modifications of this invention using the synthetic pathways described above will be obvious to those skilled in the art.

Typically, the compounds of formula I used in the 10 composition of the invention will have an IC<sub>50</sub> for inhibiting poly(ADP-ribose) polymerase in vitro of 100 µM or lower, preferably 25 µM or lower, more preferably 12 µM or lower and, even more preferably, 12 mM or lower.

#### 15 Pharmaceutical Compositions

A further aspect of the present invention is directed to a pharmaceutical composition comprising a pharmaceutically acceptable carrier or a diluent and a therapeutically effective amount of a compound of formula I or a pharmaceutically acceptable salt, hydrate, ester, solvate, prodrug, metabolite, stereoisomer, or mixtures (hereafter, "a compound of formula I").

The formula I compounds of the invention are useful in the manufacture of pharmaceutical formulations comprising an 25 effective amount thereof in conjunction with or as an admixture with excipients or carriers suitable for either enteral or parenteral application. As such, formulations of the present invention suitable for oral administration may be in the form of discrete units such as capsules, cachets, tablets, troche or 30 lozenges, and the like, each containing a predetermined amount of the active ingredient; in the form of a powder or granules; in the form of a solution or a suspension in an aqueous liquid or nonaqueous liquid; or in the form of an oil-in-water emulsion or a water-in-oil emulsion. The active ingredient may also be

in the form of a bolus, electuary, or paste. Each formulation may contain from about 0.01% to about 99.99% by weight, preferably from about 3.5% to about 60% by weight, of the compound of the invention, as well as one or more pharmaceutical excipients, such as wetting, emulsifying and pH buffering agents.

The composition will usually be formulated into a unit dosage form, such as a tablet, capsule, aqueous suspension or solution. Such formulations typically include a solid, 10 semisolid, or liquid carrier. Exemplary carriers include lactose, dextrose, sucrose, sorbitol, mannitol, starches, gum acacia, calcium phosphate, mineral oil, cocoa butter, oil of theobroma, alginates, tragacanth, gelatin, syrup, methyl cellulose, polyoxyethylene sorbitan monolaurate, methyl 15 hydroxybenzoate, propyl hydroxybenzoate, talc, magnesium stearate, corn starch and the like.

Particularly preferred formulations include tablets and gelatin capsules comprising the active ingredient together with (a) diluents, such as lactose, dextrose, sucrose, mannitol, 20 sorbitol, cellulose, dried corn starch, and glycine, and the like; and/or (b) lubricants, such as silica, talcum, stearic acid, its magnesium or calcium salt, and polyethylene glycol, and the like.

Tablets may also contain binders, such as magnesium 25 aluminum silicate, starch paste, gelatin, tragacanth, methylcellulose, sodium carboxymethylcellulose and polyvinylpyrrolidone; disintegrants, such as starches, agar, alginic acid or its sodium salt, and effervescent mixtures; and/or absorbents, colorants, flavors, and sweeteners. The 30 compositions of the invention may be sterilized and/or contain adjuvants, such as preserving, stabilizing, swelling or emulsifying agents, solution promoters, salts for regulating osmotic pressure, and/or buffers. In addition, the composition may also contain other therapeutically valuable substances.

Aqueous suspensions may contain emulsifying and suspending agents combined with the active ingredient. All oral dosage forms may further contain sweetening and/or flavoring and/or coloring agents.

5 These compositions are prepared according to conventional mixing, granulating, or coating methods, respectively, and contain about 0.1 to 75% of the active ingredient, preferably about 1 to 50% of the same. A tablet may be made by compressing or molding the active ingredient optionally with one or more  
10 accessory ingredients. Compressed tablets may be prepared by compressing, in a suitable machine, the active ingredient in a free-flowing form such as a powder or granules, optionally mixed with a binder, lubricant, inert diluent, surface active, or dispersing agent. Molded tablets may be made by molding, in a  
15 suitable machine, a mixture of the powdered active ingredient and a suitable carrier moistened with an inert liquid diluent.

When administered parenterally, the composition will normally be in a unit dosage, sterile injectable form (aqueous isotonic solution, suspension or emulsion) with a  
20 pharmaceutically acceptable carrier. Such carriers are preferably non-toxic, parenterally-acceptable and contain non-therapeutic diluents or solvents. Examples of such carriers include water; aqueous solutions, such as saline (isotonic sodium chloride solution), Ringer's solution, dextrose solution,  
25 and Hanks' solution; and nonaqueous carriers, such as 1,3-butanediol, fixed oils (e.g., corn, cottonseed, peanut, sesame oil, and synthetic mono- or di-glyceride), ethyl oleate, and isopropyl myristate.

Oleaginous suspensions can be formulated according to  
30 techniques known in the art using suitable dispersing or wetting agents and suspending agents. Among the acceptable solvents or suspending mediums are sterile fixed oils. For this purpose, any bland fixed oil may be used. Fatty acids, such as oleic acid and its glyceride derivatives, including olive oil and

castor oil, especially in their polyoxyethylated forms, are also useful in the preparation of injectables. These oil solutions or suspensions may also contain long-chain alcohol diluents or dispersants.

5        Sterile saline is a preferred carrier, and the compounds are often sufficiently water soluble to be made up as a solution for all foreseeable needs. The carrier may contain minor amounts of additives, such as substances that enhance solubility, isotonicity, and chemical stability, e.g., anti-  
10      oxidants, buffers and preservatives.

When administered rectally, the composition will usually be formulated into a unit dosage form such as a suppository or cachet. These compositions can be prepared by mixing the compound with suitable non-irritating excipients that are solid  
15      at room temperature, but liquid at rectal temperature, such that they will melt in the rectum to release the compound. Common excipients include cocoa butter, beeswax and polyethylene glycols or other fatty emulsions or suspensions.

Moreover, the compounds may be administered topically,  
20      especially when the conditions addressed for treatment involve areas or organs readily accessible by topical application, including neurological disorders of the eye, the skin or the lower intestinal tract.

For topical application to the eye, or ophthalmic use, the  
25      compounds can be formulated as micronized suspensions in isotonic, pH-adjusted sterile saline or, preferably, as a solution in isotonic, pH-adjusted sterile saline, either with or without a preservative such as benzylalkonium chloride. Alternatively, the compounds may be formulated into ointments,  
30      such as petrolatum.

For topical application to the skin, the compounds can be formulated into suitable ointments containing the compounds suspended or dissolved in, for example, mixtures with one or more of the following: mineral oil, liquid petrolatum, white

petrolatum, propylene glycol, polyoxyethylene compound, polyoxypropylene compound, emulsifying wax and water. Alternatively, the compounds can be formulated into suitable lotions or creams containing the active compound suspended or 5 dissolved in, for example, a mixture of one or more of the following: mineral oil, sorbitan monostearate, polysorbate 60, cetyl ester wax, cetearyl alcohol, 2-octyldodecanol, benzyl alcohol and water.

Topical application to the lower intestinal tract can be 10 effected in rectal suppository formulations (see above) or in suitable enema formulations.

Formulations suitable for nasal or buccal administration, (such as self-propelling powder dispensing formulations), may comprise about 0.1% to about 5% w/w of the active ingredient or, 15 for example, about 1% w/w of the same. In addition, some formulations can be compounded into a sublingual troche or lozenge.

The formulations may conveniently be presented in unit dosage form and may be prepared by any of the methods well known 20 in the art of pharmacy. All methods include the step of bringing the active ingredient into association with the carrier which constitutes one or more accessory ingredients. In general, the formulations are prepared by uniformly and intimately bringing the active ingredient into association with 25 a liquid carrier or a finely divided solid carrier or both, and then, if necessary, shaping the product into the desired formulation.

In a preferred embodiment, the carrier is a solid biodegradable polymer or mixture of biodegradable polymers with 30 appropriate time release characteristics and release kinetics. The composition of the invention may then be molded into a solid implant suitable for providing efficacious concentrations of the compounds of the invention over a prolonged period of time without the need for frequent re-dosing. The composition of the

present invention can be incorporated into the biodegradable polymer or polymer mixture in any suitable manner known to one of ordinary skill in the art and may form a homogeneous matrix with the biodegradable polymer, or may be encapsulated in some 5 way within the polymer, or may be molded into a solid implant.

In one embodiment, the biodegradable polymer or polymer mixture is used to form a soft "depot" containing the pharmaceutical composition of the present invention that can be administered as a flowable liquid, for example, by injection, 10 but which remains sufficiently viscous to maintain the pharmaceutical composition within the localized area around the injection site. The degradation time of the depot so formed can be varied from several days to a few years, depending upon the polymer selected and its molecular weight. By using a polymer 15 composition in injectable form, even the need to make an incision may be eliminated. In any event, a flexible or flowable delivery "depot" will adjust to the shape of the space it occupies with the body with a minimum of trauma to surrounding tissues. The pharmaceutical composition of the 20 present invention is used in amounts that are therapeutically effective, and may depend upon the desired release profile, the concentration of the pharmaceutical composition required for the sensitizing effect, and the length of time that the pharmaceutical composition has to be released for treatment.

25 The composition of the invention is preferably administered as a capsule or tablet containing a single dose or a series of divided doses of the compound, or as a sterile solution, suspension, or emulsion, for parenteral administration in a single or divided dose.

30 In another preferred embodiment, the compounds of the invention can be prepared in lyophilized form. In this case, 1 to 100 mg of a PARP inhibitor may be lyophilized in individual vials, together with a carrier and a buffer, such as mannitol and sodium phosphate. The composition may then be reconstituted

in the vials with bacteriostatic water before administration.

The compounds of the invention are used in the composition in amounts that are therapeutically effective. While the effective amount of the PARP inhibitor will depend upon the 5 particular compound being used, amounts of these compounds varying from about 1% to about 65% have been easily incorporated into liquid or solid carrier delivery systems.

Compositions and Methods for Effecting Neuronal Activity

10 Preferably, the compounds of the invention inhibit PARP activity and, thus, are believed to be useful for treating neural tissue damage, particularly damage resulting from cerebral ischemia and reperfusion injury or neurodegenerative diseases in animals. The term "nervous tissue" refers to the 15 various components that make up the nervous system including, without limitation, neurons, neural support cells, glia, Schwann cells, vasculature contained within and supplying these structures, the central nervous system, the brain, the brain stem, the spinal cord, the junction of the central nervous 20 system with the peripheral nervous system, the peripheral nervous system, and allied structures. Further, according to the invention, an effective therapeutic amount of the compounds and compositions described above are administered to animals to effect a neuronal activity, particularly one that is 25 not mediated by NMDA neurotoxicity. Such neuronal activity may consist of stimulation of damaged neurons, promotion of neuronal regeneration, prevention of neurodegeneration and treatment of a neurological disorder. Accordingly, the present invention further relates to a method of effecting a neuronal activity in 30 an animal, comprising administering an effective amount of the compound of formula I to said animal.

Examples of neurological disorders that are treatable by the method of using the present invention include, without limitation, trigeminal neuralgia; glossopharyngeal neuralgia;

Bell's Palsy; myasthenia gravis; muscular dystrophy; amyotrophic lateral sclerosis; progressive muscular atrophy; progressive bulbar inherited muscular atrophy; herniated, ruptured or prolapsed invertebrate disk syndromes; cervical spondylosis; 5 plexus disorders; thoracic outlet destruction syndromes; peripheral neuropathies such as those caused by lead, dapsone, ticks, porphyria, or Guillain-Barré syndrome; Alzheimer's disease; Huntington's Disease and Parkinson's disease. The term "neurodegenerative diseases" includes Alzheimer's disease, 10 Parkinson's disease and Huntington's disease. The term "nervous insult" refers to any damage to nervous tissue and any disability or death resulting therefrom. The cause of nervous insult may be metabolic, toxic, neurotoxic, iatrogenic, thermal or chemical, and includes without limitation, ischemia, hypoxia, 15 cerebrovascular accident, trauma, surgery, pressure, mass effect, hemorrhage, radiation, vasospasm, neurodegenerative disease, infection, Parkinson's disease, amyotrophic lateral sclerosis (ALS), myelination/demyelination process, epilepsy, cognitive disorder, glutamate abnormality and secondary effects 20 thereof.

The term "neuroprotective" refers to the effect of reducing, arresting or ameliorating nervous insult, and protecting, resuscitating, or reviving nervous tissue that has suffered nervous insult.

25 The term "preventing neurodegeneration" includes the ability to prevent neurodegeneration in patients diagnosed as having a neurodegenerative disease or who are at risk of developing a neurodegenerative disease. The term also encompasses preventing further neurodegeneration in patients who 30 are already suffering from or have symptoms of a neurodegenerative disease.

The term "treating" refers to:

(i) preventing a disease, disorder or condition from occurring in an animal that may be predisposed to the disease,

disorder and/or condition, but has not yet been diagnosed as having it;

(ii) inhibiting the disease, disorder or condition, i.e., arresting its development; and

5 (iii) relieving the disease, disorder or condition, i.e., causing regression of the disease, disorder and/or condition.

The method of the present invention is particularly useful for treating a neurological disorder selected from the group consisting of: peripheral neuropathy caused by physical injury  
10 or disease state; head trauma, such as traumatic brain injury; physical damage to the spinal cord; stroke associated with brain damage, such as vascular stroke associated with hypoxia and brain damage, focal cerebral ischemia, global cerebral ischemia, and cerebral reperfusion injury; demyelinating diseases, such  
15 as multiple sclerosis; and neurological disorders related to neurodegeneration, such as Alzheimer's Disease, Parkinson's Disease, Huntington's Disease and amyotrophic lateral sclerosis (ALS).

The term "neural tissue damage resulting from ischemia and  
20 reperfusion injury and neurodegenerative diseases" includes neurotoxicity, such as seen in vascular stroke and global and focal ischemia.

#### Treating Other PARP-Related Disorders

25 The compounds, compositions and methods of the present invention are particularly useful for treating or preventing tissue damage resulting from cell death or damage due to necrosis or apoptosis.

The compounds, compositions and methods of the invention  
30 can also be used to treat a cardiovascular disorder in an animal, by administering an effective amount of the compound or formula to the animal. As used herein, the term "cardiovascular disorders" refers to those disorders that can either cause ischemia or are caused by reperfusion of the heart. Examples

include, but are not limited to, coronary artery disease, angina pectoris, myocardial infarction, cardiovascular tissue damage caused by cardiac arrest, cardiovascular tissue damage caused by cardiac bypass, cardiogenic shock, and related conditions 5 that would be known by those of ordinary skill in the art or which involve dysfunction of or tissue damage to the heart or vasculature, especially, but not limited to, tissue damage related to PARP activation.

For example, the methods of the invention are believed to 10 be useful for treating cardiac tissue damage, particularly damage resulting from cardiac ischemia or caused by reperfusion injury in animals. The methods of the invention are particularly useful for treating cardiovascular disorders selected from the group consisting of: coronary artery disease, 15 such as atherosclerosis; angina pectoris; myocardial infarction; myocardial ischemia and cardiac arrest; cardiac bypass; and cardiogenic shock. The methods of the invention are particularly helpful in treating the acute forms of the above cardiovascular disorders.

Further, the methods of the invention can be used to treat 20 tissue damage resulting from cell damage or death due to necrosis or apoptosis, neural tissue damage resulting from ischemia and reperfusion injury, neurological disorders and neurodegenerative diseases; to prevent or treat vascular stroke; 25 to treat or prevent cardiovascular disorders; to treat other conditions and/or disorders such as age-related macular degeneration, AIDS and other immune senescence diseases, arthritis, atherosclerosis, cachexia, cancer, degenerative diseases of skeletal muscle involving replicative senescence, 30 diabetes, head trauma, immune senescence, inflammatory bowel disorders (such as colitis and Crohn's disease), muscular dystrophy, osteoarthritis, osteoporosis, chronic and/or acute pain (such as neuropathic pain), renal failure, retinal ischemia, septic shock (such as endotoxic shock), and skin

aging; to extend the lifespan and proliferative capacity of cells; to alter gene expression of senescent cells; or to radiosensitize tumor cells

Further still, the methods of the invention can be used to treat cancer and to radiosensitize tumor cells. The term "cancer" is interpreted broadly. The compounds of the present invention can be "anti-cancer agents", which term also encompasses "anti-tumor cell growth agents" and "anti-neoplastic agents". For example, the methods of the invention are useful for treating cancers and radiosensitizing tumor cells in cancers such as ACTH-producing tumors, acute lymphocytic leukemia, acute nonlymphocytic leukemia, cancer of the adrenal cortex, bladder cancer, brain cancer, breast cancer, cervical cancer, chronic lymphocytic leukemia, chronic myelocytic leukemia, colorectal cancer, cutaneous T-cell lymphoma, endometrial cancer, esophageal cancer, Ewing's sarcoma, gallbladder cancer, hairy cell leukemia, head & neck cancer, Hodgkin's lymphoma, Kaposi's sarcoma, kidney cancer, liver cancer, lung cancer (small and/or non-small cell), malignant peritoneal effusion, malignant pleural effusion, melanoma, mesothelioma, multiple myeloma, neuroblastoma, non-Hodgkin's lymphoma, osteosarcoma, ovarian cancer, ovary (germ cell) cancer, prostate cancer, pancreatic cancer, penile cancer, retinoblastoma, skin cancer, soft-tissue sarcoma, squamous cell carcinomas, stomach cancer, testicular cancer, thyroid cancer, trophoblastic neoplasms, uterine cancer, vaginal cancer, cancer of the vulva and Wilm's tumor.

The term "radiosensitizer", as used herein, is defined as a molecule, preferably a low molecular weight molecule, administered to animals in therapeutically effective amounts to increase the sensitivity of the cells to be radiosensitized to electromagnetic radiation and/or to promote the treatment of diseases which are treatable with electromagnetic radiation. Diseases which are treatable with electromagnetic radiation include neoplastic diseases, benign and malignant tumors, and

cancerous cells. Electromagnetic radiation treatment of other diseases not listed herein are also contemplated by the present invention. The terms "electromagnetic radiation" and "radiation" as used herein includes, but is not limited to, 5 radiation having the wavelength of  $10^{-20}$  to  $10^0$  meters. Preferred embodiments of the present invention employ the electromagnetic radiation of: gamma-radiation ( $10^{-20}$  to  $10^{-13}$  m) x-ray radiation ( $10^{-11}$  to  $10^{-9}$  m), ultraviolet light (10 nm to 400 nm), visible light (400 nm to 700 nm), infrared radiation (700 10 nm to 1.0 mm), and microwave radiation (1 mm to 30 cm).

Radiosensitizers are known to increase the sensitivity of cancerous cells to the toxic effects of electromagnetic radiation. Several mechanisms for the mode of action of radiosensitizers have been suggested in the literature 15 including: hypoxic cell radiosensitizers (e.g., 2-nitroimidazole compounds, and benzotriazine dioxide compounds) promote the reoxygenation of hypoxic tissue and/or catalyze the generation of damaging oxygen radicals; non-hypoxic cell radiosensitizers (e.g., halogenated pyrimidines) can be analogs 20 of DNA bases and preferentially incorporate into the DNA of cancer cells and thereby promote the radiation-induced breaking of DNA molecules and/or prevent the normal DNA repair mechanisms; and various other potential mechanisms of action have been hypothesized for radiosensitizers in the treatment of 25 disease.

Many cancer treatment protocols currently employ radiosensitizers activated by the electromagnetic radiation of x-rays. Examples of x-ray activated radiosensitizers include, but are not limited to, the following: metronidazole, 30 misonidazole, desmethylmisonidazole, pimonidazole, etanidazole, nimorazole, mitomycin C, RSU 1069, SR 4233, EO9, RB 6145, nicotinamide, 5-bromodeoxyuridine (BUdR), 5-iododeoxyuridine (IUDR), bromodeoxycytidine, fluorodeoxyuridine (FudR), hydroxyurea, cisplatin, and therapeutically effective analogs

and derivatives of the same.

Photodynamic therapy (PDT) of cancers employs visible light as the radiation activator of the sensitizing agent. Examples of photodynamic radiosensitizers include the following, but are 5 not limited to: hematoporphyrin derivatives, Photofrin, benzoporphyrin derivatives, NPe6, tin etioporphyrin SnET2, pheoborbide-a, bacteriochlorophyll-a, naphthalocyanines, phthalocyanines, zinc phthalocyanine, and therapeutically effective analogs and derivatives of the same.

10       Radiosensitizers may be administered in conjunction with a therapeutically effective amount of one or more other compounds, including but not limited to: compounds which promote the incorporation of radiosensitizers to the target cells; compounds which control the flow of therapeutics, nutrients, 15 and/or oxygen to the target cells; chemotherapeutic agents which act on the tumor with or without additional radiation; or other therapeutically effective compounds for treating cancer or other disease. Examples of additional therapeutic agents that may be used in conjunction with radiosensitizers include, but are not 20 limited to: 5-fluorouracil, leucovorin, 5'-amino-5'deoxythymidine, oxygen, carbogen, red cell transfusions, perfluorocarbons (e.g., Fluosol-DA), 2,3-DPG, BW12C, calcium channel blockers, pentoxyfylline, antiangiogenesis compounds, hydralazine, and L-BSO. Examples of chemotherapeutic agents 25 that may be used in conjunction with radiosensitizers include, but are not limited to: adriamycin, camptothecin, carboplatin, cisplatin, daunorubicin, docetaxel, doxorubicin, interferon (alpha, beta, gamma), interleukin 2, irinotecan, paclitaxel, topotecan, and therapeutically effective analogs and derivatives 30 of the same.

The compounds of the present invention may also be used for radiosensitizing tumor cells.

The term "treating" refers to:

- (i) preventing a disease, disorder or condition from

occurring in an animal that may be predisposed to the disease, disorder and/or condition, but has not yet been diagnosed as having it;

(ii) inhibiting the disease, disorder or condition, i.e.,  
5 arresting its development; and

(iii) relieving the disease, disorder or condition, i.e., causing regression of the disease, disorder and/or condition.

Administration

10 For medical use, the amount required of a compound of formula I to achieve a therapeutic effect will vary according to the particular compound administered, the route of administration, the animal under treatment, and the particular disorder or disease concerned. A suitable systemic dose of a  
15 compound of formula I for an animal suffering from, or likely to suffer from, any condition as described herein is typically in the range of about 0.1 to about 100 mg of base per kilogram of body weight, preferably from about 1 to about 10 mg/kg of animal body weight. It is understood that the ordinarily  
20 skilled physician or veterinarian will readily be able to determine and prescribe the amount of the compound effective for the desired prophylactic or therapeutic treatment.

In so proceeding, the physician or veterinarian may employ an intravenous bolus followed by an intravenous infusion and  
25 repeated administrations, as considered appropriate. In the methods of the present invention, the compounds may be administered, for example, orally, parenterally, by inhalation spray, topically, rectally, nasally, buccally, sublingually, vaginally, intraventricularly, or via an implanted reservoir in  
30 dosage formulations containing conventional non-toxic pharmaceutically-acceptable carriers, adjuvants and vehicles.

Parenteral includes, but is not limited to, the following examples of administration: intravenous, subcutaneous,

intramuscular, intraspinal, intraosseous, intraperitoneal, intrathecal, intraventricular, intrasternal or intracranial injection and infusion techniques, such as by subdural pump. Invasive techniques are preferred, particularly direct 5 administration to damaged neuronal tissue. While it is possible for the compound of formula I to be administered alone, it is preferable to provide it as a part of a pharmaceutical formulation.

To be effective therapeutically as central nervous system 10 targets, the compounds used in the methods of the present invention should readily penetrate the blood-brain barrier when peripherally administered. Compounds which cannot penetrate the blood-brain barrier, however, can still be effectively administered by an intraventricular route.

15 The compounds used in the methods of the present invention may be administered by a single dose, multiple discrete doses or continuous infusion. Since the compounds are small, easily diffusible and relatively stable, they are well suited to continuous infusion. Pump means, particularly subcutaneous or 20 subdural pump means, are preferred for continuous infusion.

For the methods of the present invention, any effective administration regimen regulating the timing and sequence of doses may be used. Doses of the compounds preferably include pharmaceutical dosage units comprising an efficacious quantity 25 of active compound. By an efficacious quantity is meant a quantity sufficient to inhibit PARP activity and/or derive the desired beneficial effects therefrom through administration of one or more of the pharmaceutical dosage units. In a particularly preferred embodiment, the dose is sufficient to 30 prevent or reduce the effects of vascular stroke or other neurodegenerative diseases.

An exemplary daily dosage unit for a vertebrate host comprises an amount of from about 0.001 mg/kg to about 50 mg/kg. Typically, dosage levels on the order of about 0.1 mg to about

10,000 mg of the active ingredient compound are useful in the treatment of the above conditions, with preferred levels being about 0.1 mg to about 1,000 mg. The specific dose level for any particular patient will vary depending upon a variety of factors, including the activity of the specific compound employed; the age, body weight, general health, sex, and diet of the patient; the time of administration; the rate of excretion; any combination of the compound with other drugs; the severity of the particular disease being treated; and the form and route of administration. Typically, in vitro dosage-effect results provide useful guidance on the proper doses for patient administration. Studies in animal models can also be helpful. The considerations for determining the proper dose levels are well-known in the art.

In methods of treating nervous insult (particularly acute ischemic stroke and global ischemia caused by drowning or head trauma), the compounds of the invention can be co-administered with one or more other therapeutic agents, preferably agents which can reduce the risk of stroke (such as aspirin) and, more preferably, agents which can reduce the risk of a second ischemic event (such as ticlopidine).

The compounds and compositions can be co-administered with one or more therapeutic agents either (i) together in a single formulation, or (ii) separately in individual formulations designed for optimal release rates of their respective active agent. When the compounds used in the methods of the invention are administered in combination with one or more other therapeutic agents, specific dose levels for those agents will depend upon considerations such as those identified above for compositions and methods of the invention in general.

For example, Table II below provides known median dosages for selected chemotherapeutic agents that may be administered in combination with the compounds of the invention to such diseases or various cancers.

TABLE II

CHEMOTHERAPEUTIC AGENT	MEDIAN DOSAGE
Asparaginase	10,000 units
Bleomycin Sulfate	15 units
Carboplatin	50-450 mg
Carmustine	100 mg
Cisplatin	10-50 mg
Cladribine	10 mg
Cyclophosphamide (lyophilized)	100 mg to 2 gm
Cyclophosphamide (non-lyophilized)	100 mg to 2 gm
Cytarabine (lyophilized powder)	100 mg to 2 gm
Dacarbazine	100-200 mg
Dactinomycin	0.5 mg
Daunorubicin	20 mg
Diethylstilbestrol	250 mg
Doxorubicin	10-150 mg
Etidronate	300 mg
Etoposide	100 mg
Floxuridine	500 mg
Fludarabine Phosphate	50 mg
Fluorouracil	500 mg to 5 gm
Goserelin	3.6 mg
Granisetron Hydrochloride	1 mg
Idarubicin	5-10 mg
Ifosfamide	1-3 gm
Leucovorin Calcium	50-350 mg
Leuprolide	3.75-7.5 mg
Mechlorethamine	10 mg
Medroxyprogesterone	1 gm
Malphalan	50 gm
Methotrexate	20 mg to 1 gm
Mitomycin	5-40 mg

CHEMOTHERAPEUTIC AGENT	MEDIAN DOSAGE
Mitoxantrone	20-30 mg
Ondansetron Hydrochloride	40 mg
Paclitaxel	30 mg
Pamidronate Disodium	30-90 mg
5 Pegaspargase	750 units
Plicamycin	2,500 mcgm
Streptozocin	1 gm
Thiotepa	15 mg
Teniposide	50 mg
10 Vinblastine	10 mg
Vincristine	1-5 mg
Aldesleukin	22 million units
Epoetin Alfa	2,000-10,000 units
Filgrastim	300-480 mcgm
15 Immune Globulin	500 mg to 10 gm
Interferon Alpha-2a	3-36 million units
Interferon Alpha-2b	3-50 million units
Levamisole	50 mg
Octreotide	1,000-5,000 mcgm
20 Sargramostim	250-500 mcgm

For the methods of the present invention, any administration regimen regulating the timing and sequence of delivery of the compound can be used and repeated as necessary 25 to effect treatment. Such regimen may include pretreatment and/or co-administration with additional therapeutic agents.

To maximize protection of nervous tissue from nervous insult, the compounds of the invention should be administered to the affected cells as soon as possible. In situations where 30 nervous insult is anticipated, the compounds are advantageously administered before the expected nervous insult. Such situations of increased likelihood of nervous insult include

surgery, such as carotid endarterectomy, cardiac, vascular, aortic, orthopedic surgery; endovascular procedures, such as arterial catheterization (carotid, vertebral, aortic, cardia, renal, spinal, Adamkiewicz); injections of embolic agents; the 5 use of coils or balloons for hemostasis; interruptions of vascularity for treatment of brain lesions; and predisposing medical conditions such as crescendo transient ischemic attacks, emboli and sequential strokes.

Where pre-treatment for stroke or ischemia is impossible 10 or impracticable, it is important to bring the compounds of the invention into contact with the affected cells as soon as possible, either during or after the event. In the time period between strokes, however, diagnosis and treatment procedures should be minimized to save the cells from further damage and 15 death. Therefore, a particularly advantageous mode of administration with a patient diagnosed with acute multiple vascular strokes is by implantation of a subdural pump to deliver the compound(s) of the invention directly to the infarct area of the brain. Even if comatose, it is expected that the 20 patient would recover more quickly than he or she would without this treatment. Moreover, in any conscious state of the patient, it is expected that any residual neurological symptoms, as well as the re-occurrence of stroke, would be reduced.

As to patients diagnosed with other acute disorders 25 believed to be related to PARP activity, such as diabetes, arthritis and Crohn's disease, the compound of the invention should also be administered as soon as possible in a single or divided dose.

Depending on the patient's presenting symptoms and the 30 degree of response to the initial administration of the compound of the invention, the patient may further receive additional doses of the same or different compounds of the invention, by one of the following routes: parenterally, such as by injection or by intravenous administration; orally, such as by capsule or

tablet; by implantation of a biocompatible, biodegradable polymeric matrix delivery system comprising the compound; or by direct administration to the infarct area by insertion of a subdural pump or a central line. It is expected that the 5 treatment would alleviate the disorder, either in part or in its entirety and that fewer further occurrences of the disorder would develop. It also is expected that the patient would suffer fewer residual symptoms.

Where a patient is diagnosed with an acute disorder prior 10 to the availability of the compounds of the invention, the patient's condition may deteriorate due to the acute disorder and become a chronic disorder by the time that the compounds are available. Even when a patient receives a compound of formula I for the chronic disorder, it is also expected that the 15 patient's condition would stabilize and actually improve as a result of receiving the compound. The compounds of the present invention may also be used to prevent disorders by prophylactic administration of the compounds of the present invention.

20

#### EXAMPLES

The following examples are illustrative of preferred embodiments of related inventions and are not to be construed as limiting the present invention thereto. All polymer molecular weights are mean average molecular weights. All 25 percentages are based on the percent by weight of the final delivery system or formulation prepared unless otherwise indicated, and all totals equal 100% by weight.




##### Example 1: Approximate IC<sub>50</sub> Data for Selected Compounds




30 The IC<sub>50</sub> of with respect to PARP inhibition was determined for several compounds by a PARP assay using purified recombinant human PARP from Trevigen (Gaithersburg, MD), as follows: The PARP enzyme assay was set up on ice in a volume of 100 microliters consisting of 10 mM Tris-HCl (pH 8.0), 1 mM MgCl<sub>2</sub>,





28 mM KCl, 28 mM NaCl, 0.1 mg/ml of herring sperm DNA (activated as a 1 mg/ml stock for 10 minutes in a 0.15% hydrogen peroxide solution), 3.0 micromolar [<sup>3</sup>H]nicotinamide adenine dinucleotide (470 mci/mmol), 7 micrograms/ml PARP enzyme, and various 5 concentrations of the compounds to be tested. The reaction was initiated by incubating the mixture at 25°C. After 15 minutes' incubation, the reaction was terminated by adding 500 microliters of ice cold 20% (w/v) trichloroacetic acid. The precipitate formed was transferred onto a glass fiber filter 10 (Packard Unifilter-GF/B) and washed three times with ethanol. After the filter was dried, the radioactivity was determined by scintillation counting.

Using the PARP assay described above, approximate IC<sub>50</sub> values were obtained for the following compounds:

15

PARP Inhibitor	Approximate IC <sub>50</sub> 's
	.25 μM
	5 μM
	30 μM

PARP Inhibitor	Approximate IC <sub>50</sub> 's
	10 μM
	10 μM
	50 μM
	0.8 μM
	4 μM

PARP Inhibitor	Approximate IC <sub>50</sub> 's
	100 $\mu$ M
	0.9 $\mu$ M
	5.2 $\mu$ M
	0.7 $\mu$ M

PARP Inhibitor	Approximate IC <sub>50</sub> 's
	1.1 μM

Similar IC<sub>50</sub> values are obtained for the thioalkyl compounds of the invention.

5

Example 2: Neuroprotective Effect of DPQ on Focal Cerebral Ischemia in Rats

Focal cerebral ischemia was produced by cauterization of the right distal MCA (middle cerebral artery) with bilateral 10 temporary common carotid artery occlusion in male Long-Evans rats for 90 minutes. All procedures performed on the animals were approved by the University Institutional Animal Care and Use Committee of the University of Pennsylvania. A total of 42 rats (weights: 230-340 g) obtained from Charles River were used 15 in this study. The animals fasted overnight with free access to water prior to the surgical procedure.

Two hours prior to MCA occlusion, varying amounts (control, n=14; 5 mg/kg, n=7; 10 mg/kg, n=7; 20 mg/kg, n=7; and 40 mg/kg, n=7) of the non-thioalkyl compound, 3,4-dihydro-5-[4-(1-piperidinyl)-butoxy]-1(2H)-isoquinolinone ("DPQ") were dissolved 20 in dimethyl sulfoxide (DMSO) using a sonicator. A volume of 1.28 ml/kg of the resulting solution was injected intraperitoneally into fourteen rats.

The rats were then anesthetized with halothane (4% for 25 induction and 0.8%-1.2% for the surgical procedure) in a mixture of 70% nitrous oxide and 30% oxygen. The body temperature was monitored by a rectal probe and maintained at 37.5 ± 0.5°C with

a heating blanket regulated by a homeothermic blanket control unit (Harvard Apparatus Limited, Kent, U.K.). A catheter (PE-50) was placed into the tail artery, and arterial pressure was continuously monitored and recorded on a Grass polygraph recorder (Model 7D, Grass Instruments, Quincy, Massachusetts). Samples for blood gas analysis (arterial pH, PaO<sub>2</sub> and PaCO<sub>2</sub>) were also taken from the tail artery catheter and measured with a blood gas analyzer (ABL 30, Radiometer, Copenhagen, Denmark). Arterial blood samples were obtained 30 minutes after MCA occlusion.

The head of the animal was positioned in a stereotaxic frame, and a right parietal incision between the right lateral canthus and the external auditory meatus was made. Using a dental drill constantly cooled with saline, a 3 mm burr hole was prepared over the cortex supplied by the right MCA, 4 mm lateral to the sagittal suture and 5 mm caudal to the coronal suture. The dura mater and a thin inner bone layer were kept, care being taken to position the probe over a tissue area devoid of large blood vessels. The flow probe (tip diameter of 1 mm, fiber separation of 0.25 mm) was lowered to the bottom of the cranial burr hole using a micromanipulator. The probe was held stationary by a probe holder secured to the skull with dental cement. The microvascular blood flow in the right parietal cortex was continuously monitored with a laser Doppler flowmeter (FloLab, Moor, Devon, U.K., and Periflux 4001, Perimed, Stockholm, Sweden).

Focal cerebral ischemia was produced by cauterization of the distal portion of the right MCA with bilateral temporary common carotid artery (CCA) occlusion by the procedure of Chen et al., "A Model of Focal Ischemic Stroke in the Rat: Reproducible Extensive Cortical Infarction", *Stroke* 17:738-43 (1986) and/or Liu et al., "Polyethylene Glycol-conjugated Superoxide Dismutase and Catalase Reduce Ischemic Brain Injury", *Am. J. Physiol.* 256:H589-93 (1989), both of which are hereby

incorporated by reference.

Specifically, bilateral CCA's were isolated, and loops made from polyethylene (PE-10) catheter were carefully passed around the CCA's for later remote occlusion. The incision made 5 previously for placement of the laser doppler probe was extended to allow observation of the rostral end of the zygomatic arch at the fusion point using a dental drill, and the dura mater overlying the MCA was cut. The MCA distal to its crossing with the inferior cerebral vein was lifted by a fine stainless steel 10 hook attached to a micromanipulator and, following bilateral CCA occlusion, the MCA was cauterized with an electrocoagulator. The burr hole was covered with a small piece of Gelform, and the wound was sutured to maintain the brain temperature within the normal or near-normal range.

15 After 90 minutes of occlusion, the carotid loops were released, the tail arterial catheter was removed, and all of the wounds were sutured. Gentamicin sulfate (10 mg/ml) was topically applied to the wounds to prevent infection. The anesthetic was discontinued, and the animal was returned to his 20 cage after awakening. Water and food were allowed ad libitum.

Two hours after MCA occlusion, the animals were given the same doses of the PARP inhibitor as in the pre-treatment. Twenty-four hours after MCA occlusion, the rats were sacrificed with an intraperitoneal injection of pentobarbital sodium (150 25 mg/kg). The brain was carefully removed from the skull and cooled in ice-cold artificial CSF for five minutes. The cooled brain was then sectioned in the coronal plane at 2 mm intervals using a rodent brain matrix (RBM-4000C, ASI Instruments, Warren, Michigan). The brain slices were incubated in phosphate- 30 buffered saline containing 2% 2,3,5-triphenyltetrazolium chloride (TTC) at 37°C for ten minutes. Color photographs were taken of the posterior surface of the stained slices and were used to determine the damaged area at each cross-sectional level using a computer-based image analyzer (NIH Image 1.59). To

avoid artifacts due to edema, the damaged area was calculated by subtracting the area of the normal tissue in the hemisphere ipsilateral to the stroke from the area of the hemisphere contralateral to the stroke, by the method of Swanson et al.,

5 "A Semiautomated Method for Measuring Brain Infarct Volume", *J. Cereb. Blood Flow Metabol.* 10:290-93 (1990), the disclosure of which is hereby incorporated by reference. The total volume of infarction was calculated by summation of the damaged volume of the brain slices.

10 The cauterization of the distal portion of the right MCA with bilateral temporary CCA occlusion consistently produced a well-recognized cortical infarct in the right MCA territory of each test animal. There was an apparent uniformity in the distribution of the damaged area as measured by TTC staining in 15 each group, as shown in Figure 1.

In Figure 1, the distribution of the cross-sectional infarct area at representative levels along the rostrocaudal axis was measured from the interaural line in non-treated animals and in animals treated with 10 mg/kg of 3,4-dihydro-5-20 [4-(1-piperidinyl)-butoxy]-1(2H)-isoquinolinone. The area of damage was expressed as mean  $\pm$  standard deviation. Significant differences between the 10 mg-treated group and the control group were indicated ("p<0.02, "p<0.01, "p<0.001). The 5 mg/kg and 20 mg/kg curves fell approximately halfway between the 25 control and the 10 mg/kg curves, whereas the 40 mg/kg curve was close to the control. The 5, 20 and 40 mg/kg curves were omitted for clarity.

PARP inhibition led to a significant decrease in the damaged volume in the 5 mg/kg-treated group ( $106.7 \pm 23.2 \text{ mm}^3$ , 30  $p<0.001$ ), the 10 mg/kg-treated group ( $76.4 \pm 16.8 \text{ mm}^3$ ,  $p<0.001$ ), and the 20 mg/kg-treated group ( $110.2 \pm 42.0 \text{ mm}^3$ ,  $p<0.01$ ), compared to the control group ( $165.2 \pm 34.0 \text{ mm}^3$ ). The data are expressed as mean  $\pm$  standard deviation. The significance of differences between groups was determined using an analysis of

variance (ANOVA) followed by Student's t-test for individual comparisons.

There was no significant difference between the control and the 40 mg/kg-treated group ( $135.6 \pm 44.8 \text{ mm}^3$ ). However, there 5 were significant differences between the 5 mg/kg-treated group and the 10 mg/kg-treated group ( $p<0.02$ ), and between the 10 mg/kg-treated group and the 40 mg/kg-treated group ( $p<0.01$ ), as shown in Figure 2.

In Figure 2, the effect of intraperitoneal administration 10 of 3,4-dihydro-5-[4-(1-piperidinyl)-butoxy]-1(2H)-isoquinolinone on the infarct volume was depicted graphically. The volumes of infarct were expressed as mean  $\pm$  standard deviation. Significant differences between the treated groups and the control group were indicated ( $'p<0.01$ ,  $''p<0.001$ ). It is not 15 clear why a high dose (40 mg/kg) of the PARP inhibitor, 3,4-dihydro-5-[4-(1-piperidinyl)-butoxy]-1(2H)-isoquinolinone, was less neuroprotective. The U-shaped dose-response curve may suggest dual effects of the compound.

However, overall, the in vivo administration of the 20 inhibitor led to a substantial reduction in infarct volume in the focal cerebral ischemia model in the rat. This result indicated that the activation of PARP plays an important role in the pathogenesis of brain damage in cerebral ischemia.

The values of arterial blood gases ( $\text{PaO}_2$ ,  $\text{PaCO}_2$  and pH) were 25 within the physiological range in the control and treated groups with no significant differences in these parameters among the five groups, as shown below in Table 2. A "steady state" MABP was taken following completion of the surgical preparation, just prior to occlusion; an "ischemia" MABP was taken as the average 30 MABP during occlusion. See Table III below:

TABLE III

	$\text{PaO}_2$ (mm Hg)	$\text{PaCO}_2$ (mm Hg)	pH	MABP (mm Hg) Steady Ischemia State	
Control group (n=4)	125 $\pm$ 21	38.6 $\pm$ 4.6	7.33 $\pm$ 0.05	79 $\pm$ 14	91 $\pm$ 13**
5 mg/kg-treated group (n=7)	126 $\pm$ 20	38.0 $\pm$ 2.8	7.36 $\pm$ 0.02	78 $\pm$ 5	91 $\pm$ 12**
10 mg/kg-treated group (n=7)	125 $\pm$ 16	39.3 $\pm$ 5.2	7.34 $\pm$ 0.03	80 $\pm$ 9	90 $\pm$ 14*
20 mg/kg-treated group (n=7)	122 $\pm$ 14	41.3 $\pm$ 2.8	7.35 $\pm$ 0.23	79 $\pm$ 10	91 $\pm$ 12**
40 mg/kg-treated group (n=7)	137 $\pm$ 17	39.5 $\pm$ 4.7	7.33 $\pm$ 0.24	78 $\pm$ 4	88 $\pm$ 12*

\* = Significantly different from the steady state value, p<0.05.

\*\* = Significantly different from the steady state value, p<0.01.

There were no significant differences in any physiological parameter, including mean arterial blood pressure (MABP), prior to MCA and CCA occlusion among the five groups. Although MABP was significantly elevated following occlusion in all five groups, there were no significant differences in MABP during the occlusion period among the groups.

Since the blood flow values obtained from the laser doppler were in arbitrary units, only percent changes from the baseline (prior to occlusion) were reported. Right MCA and bilateral CCA occlusion produced a significant decrease in relative blood flow in the right parietal cortex to  $20.8 \pm 7.7\%$  of the baseline in the control group (n=5),  $18.7 \pm 7.4\%$  in the 5 mg/kg-treated group (n=7),  $21.4 \pm 7.7\%$  in the 10 mg/kg-treated group (n=7) and  $19.3 \pm 11.2\%$  in the 40 mg/kg-treated group (n=7). There were no significant differences in the blood flow response to occlusion among the four groups. In addition, blood flow showed no significant changes throughout the entire occlusion period

in any group.

Following release of the carotid occlusions, a good recovery of blood flow (sometimes hyperemia) was observed in the right MCA territory of all animals. Reperfusion of the ischemic 5 tissue resulted in the formation of NO and peroxynitrite, in addition to oxygen-derived free radicals. All of these radicals have been shown to cause DNA strand breaks and to activate PARP.

This example provided evidence that the related compounds of the present invention are effective in inhibiting PARP 10 activity.

Example 3: Assay for Neuroprotective Effects on Focal Cerebral Ischemia in Rats

Focal cerebral ischemia experiments are performed using 15 male Wistar rats weighing 250 - 300 g, which are anesthetized with 4% halothane. Anesthesia is maintained with 1.0-1.5% halothane until the end of surgery. The animals are installed in a warm environment to avoid a decrease in body temperature during surgery.

An anterior midline cervical incision is made. The right common carotid artery (CCA) is exposed and isolated from the vagus nerve. A silk suture is placed and tied around the CCA in proximity to the heart. The external carotid artery (ECA) is then exposed and ligated with a silk suture. A puncture is 25 made in the CCA and a small catheter (PE 10, Ulrich & Co., St-Gallen, Switzerland) is gently advanced to the lumen of the internal carotid artery (ICA). The pterygopalatine artery is not occluded. The catheter is tied in place with a silk suture. Then, a 4-0 nylon suture (Braun Medical, Crissier, Switzerland) 30 is introduced into the catheter lumen and is pushed until the tip blocks the anterior cerebral artery. The length of catheter into the ICA is approximately 19 mm from the origin of the ECA. The suture is maintained in this position by occlusion of the catheter with heat. One cm of catheter and nylon suture are

left protruding so that the suture can be withdrawn to allow reperfusion. The skin incision is then closed with wound clips.

The animals are maintained in a warm environment during recovery from anesthesia. Two hours later, the animals are re-anesthetized, the clips are discarded, and the wound is re-opened. The catheter is cut, and the suture is pulled out. The catheter is then obturated again by heat, and wound clips are placed on the wound. The animals are allowed to survive for 24 hours with free access to food and water. The rats are then sacrificed with CO<sub>2</sub> and decapitated.

The brains are immediately removed, frozen on dry ice and stored at -80°C. The brains are then cut in 0.02 mm-thick sections in a cryocut at -19°C, selecting one of every 20 sections for further examination. The selected sections are stained with cresyl violet according to the Nissl procedure. Each stained section is examined under a light microscope, and the regional infarct area is determined according to the presence of cells with morphological changes.

Various doses of the compounds of the invention are tested in this model. The compounds are administered in either a single dose or a series of multiple doses, i.p. or i.v., at different times, both before or after the onset of ischemia. Compounds of the invention are found to provide protection from ischemia in the range of about 20 to 80%.

25

Example 4: Effects on Heart Ischemia/Reperfusion Injury in Rats

Female Sprague-Dawley rats, each weighing about 300-350 g are anesthetized with intraperitoneal ketamine at a dose of 150 mg/kg. The rats are endotracheally intubated and ventilated with oxygen-enriched room air using a Harvard rodent ventilator. Polyethylene catheters inserted into the carotid artery and the femoral vein are used for artery blood pressure monitoring and fluid administration respectively. Arterial pCO<sub>2</sub> is maintained

between 35 and 45mm Hg by adjusting the respirator rate. The rat chests are opened by median sternotomy, the pericardium is incised, and the hearts are cradled with a latex membrane tent. Hemodynamic data are obtained at baseline after at least a 15-  
5 minute stabilization period following the end of the surgical operation. The LAD (left anterior descending) coronary artery is ligated for 40 minutes, and then re-perfused for 120 minutes. After 120 minutes' reperfusion, the LAD artery is re-occluded,  
10 and a 0.1 ml bolus of monastral blue dye is injected into the left atrium to determine the ischemic risk region.

The hearts are then arrested with potassium chloride and cut into five 2-3 mm thick transverse slices. Each slice is weighed and incubated in a 1% solution of trimethyltetrazolium chloride to visualize the infarcted myocardium located within  
15 the risk region. Infarct size is calculated by summing the values for each left ventricular slice and is further expressed as a fraction of the risk region of the left ventricle.

Various doses of the compounds of the invention are tested in this model. The compounds are given either in a single dose  
20 or a series of multiple doses, i.p. or i.v., at different times, both before or after the onset of ischemia. The compounds of the invention are found to have ischemia/reperfusion injury protection in the range of 10 to 40 percent. Therefore, they protect against ischemia-induced degeneration of rat hippocampal  
25 neurons in vitro.

Example 5: Retinal Ischemia Protection

A patient just diagnosed with acute retinal ischemia is immediately administered parenterally, either by intermittent  
30 or continuous intravenous administration, a compound of formula I, either as a single dose or a series of divided doses of the compound. After this initial treatment, and depending on the patient's presenting neurological symptoms, the patient optionally may receive the same or a different compound of the

invention in the form of another parenteral dose. It is expected by the inventors that significant prevention of neural tissue damage would ensue and that the patient's neurological symptoms would considerably lessen due to the administration of  
5 the compound, leaving fewer residual neurological effects post-stroke. In addition, it is expected that the re-occurrence of retinal ischemia would be prevented or reduced.

Example 6: Treatment of Retinal Ischemia

10 A patient has just been diagnosed with acute retinal ischemia. Immediately, a physician or a nurse parenterally administers a compound of formula I, either as a single dose or as a series of divided doses. The patient also receives the same or a different PARP inhibitor by intermittent or continuous  
15 administration via implantation of a biocompatible, biodegradable polymeric matrix delivery system comprising a compound of formula I, or via a subdural pump inserted to administer the compound directly to the infarct area of the brain. It is expected by the inventors that the patient would  
20 awaken from the coma more quickly than if the compound of the invention were not administered. The treatment is also expected to reduce the severity of the patient's residual neurological symptoms. In addition, it is expected that re-occurrence of retinal ischemia would be reduced.

25

Example 7: Vascular Stroke Protection

A patient just diagnosed with acute vascular stroke is immediately administered parenterally, either by intermittent or continuous intravenous administration, a compound of formula  
30 I, either as a single dose or a series of divided doses of the compound. After this initial treatment, and depending on the patient's presenting neurological symptoms, the patient optionally may receive the same or a different compound of the invention in the form of another parenteral dose. It is

expected by the inventors that significant prevention of neural tissue damage would ensue and that the patient's neurological symptoms would considerably lessen due to the administration of the compound, leaving fewer residual neurological effects post-stroke. In addition, it is expected that the re-occurrence of vascular stroke would be prevented or reduced.

Example 8: Treatment of Vascular Stroke

A patient has just been diagnosed with acute multiple vascular strokes and is comatose. Immediately, a physician or a nurse parenterally administers a compound of formula I, either as a single dose or as a series of divided doses. Due to the comatose state of the patient, the patient also receives the same or a different PARP inhibitor by intermittent or continuous administration via implantation of a biocompatible, biodegradable polymeric matrix delivery system comprising a compound of formula I, or via a subdural pump inserted to administer the compound directly to the infarct area of the brain. It is expected by the inventors that the patient would awaken from the coma more quickly than if the compound of the invention were not administered. The treatment is also expected to reduce the severity of the patient's residual neurological symptoms. In addition, it is expected that re-occurrence of vascular stroke would be reduced.

25

Example 9: Preventing Cardiac Reperfusion Injury

A patient is diagnosed with life-threatening cardiomyopathy and requires a heart transplant. Until a donor heart is found, the patient is maintained on Extra Corporeal Oxygenation Monitoring (ECMO). A donor heart is then located, and the patient undergoes a surgical transplant procedure, during which the patient is placed on a heart-lung pump. The patient receives a compound of the invention intracardiac within a specified period of time prior to re-routing his or her

circulation from the heart-lung pump to his or her new heart, thus preventing cardiac reperfusion injury as the new heart begins to beat independently of the external heart-lung pump.

5    Example 10:    Septic Shock Assay

Groups of 10 C57/BL male mice weighing 18 to 20 g were administered a test compound, 1-carboxynaphthalene-1-carboxamide at the doses of 60, 20, 6 and 2 mg/kg, daily, by intraperitoneal (IP) injection for three consecutive days. Each animal was  
10 first challenged with lipopolysaccharide (LPS, from E. Coli, LD<sub>100</sub> of 20 mg/animal IV) plus galactosamine (20 mg/animal IV). The first dose of test compound in a suitable vehicle was given 30 minutes after challenge, and the second and third doses were given 24 hours later on day 2 and day 3 respectively, with only  
15 the surviving animals receiving the second or third dose of the test compound. Mortality was recorded every 12 hours after challenge for the three-day testing period. 1-Carboxy-naphthalene-1-carboxamide provided a protection against mortality from septic shock of about 40%.  
20 Based on these results, other compounds of the invention are expected to provide a protection against mortality exceeding about 35%.

Example 11:    In vitro Radiosensitization

25    The human prostate cancer cell line, PC-3s, were plated in 6 well dishes and grown at monolayer cultures in RPMI1640 supplemented with 10% FCS. The cells are maintained at 37°C in 5% CO<sub>2</sub> and 95% air. The cells were exposed to a dose response (0.1 mM to 0.1 µM) of 3 different PARP inhibitors of Formula I  
30 disclosed herein prior to irradiation at one sublethal dose level. For all treatment groups, the six well plates were exposed at room temperature in a Seifert 250kV/15mA irradiator with a 0.5 mm Cu/1 mm. Cell viability was examined by exclusion of 0.4% trypan blue. Dye exclusion was assessed visually by

microscopy and viable cell number was calculated by subtracting the number of cells from the viable cell number and dividing by the total number of cells. Cell proliferation rates were calculated by the amount of <sup>3</sup>H-thymidine incorporation post-  
5 irradiation. The PARP inhibitors show radiosensitization of the cells.

Example 12      *In vivo Radiosensitization*

Before undergoing radiation therapy to treat cancer, a  
10 patient is administered an effective amount of a compound or a pharmaceutical composition of the present invention. The compound or pharmaceutical composition acts as a radiosensitizer and making the tumor more susceptible to radiation therapy.

15    Example 13      Measuring Altered Gene Expression in mRNA Senescent Cells

Human fibroblast BJ cells, at Population Doubling (PDL) 94, are plated in regular growth medium and then changed to low serum medium to reflect physiological conditions described in  
20 Linskens, et al., Nucleic Acids Res. 23:16:3244-3251 (1995). A medium of DMEM/199 supplemented with 0.5% bovine calf serum is used. The cells are treated daily for 13 days with the PARP inhibitor of Formula I as disclosed herein. The control cells are treated with and without the solvent used to administer the  
25 PARP inhibitor. The untreated old and young control cells are tested for comparison. RNA is prepared from the treated and control cells according to the techniques described in PCT Publication No. 96/13610 and Northern blotting is conducted. Probes specific for senescence-related genes are analyzed, and  
30 treated and control cells compared. In analyzing the results, the lowest level of gene expression is arbitrarily set at 1 to provide a basis for comparison. Three genes particularly relevant to age-related changes in the skin are collagen, collagenase and elastin. West, Arch. Derm. 130:87-95 (1994).

Elastin expression of the cells treated with the PARP inhibitor of Formula I is significantly increased in comparison with the control cells. Elastin expression is significantly higher in young cells compared to senescent cells, and thus treatment with 5 the PARP inhibitor of Formula I causes elastin expression levels in senescent cells to change to levels similar to those found in much younger cells. Similarly, a beneficial effect is seen in collagenase and collagen expression with treatment with the PARP inhibitors of Formula I.

10

Example 14 Measuring Altered Gene Expression Protein in Senescent Cells

Approximately 105 BJ cells, at PDL 95-100 are plated and grown in 15 cm dishes. The growth medium is DMEM/199 15 supplemented with 10% bovine calf serum. The cells are treated daily for 24 hours with the PARP inhibitors of Formula I (100 µg/ 1 mL of medium). The cells are washed with phosphate buffered solution (PBS), then permeabilized with 4% paraformaldehyde for 5 minutes, then washed with PBS, and 20 treated with 100% cold methanol for 10 minutes. The methanol is removed and the cells are washed with PBS, and then treated with 10% serum to block nonspecific antibody binding. About 1 mL of the appropriate commercially available antibody solutions (1:500 dilution. Vector) is added to the cells and the mixture 25 incubated for 1 hour. The cells are rinsed and washed three times with PBS. A secondary antibody, goat anti-mouse IgG (1 mL) with a biotin tag is added along with 1 mL of a solution containing streptavidin conjugated to alkaline phosphatase and 1 mL of NBT reagent (Vector). The cells are washed and changes 30 in gene expression are noted colorimetrically. Four senescence-specific genes -- collagen I, collagen III, collagenase, and interferon gamma -- in senescent cells treated with the PARP inhibitor of Formula I are monitored and the results show a decrease in interferon gamma expression with no observable

change in the expression levels of the other three gens, demonstrating that the PARP inhibitors of Formula I can alter senescence-specific gene expression.

5    Example 15      Extending or Increasing Proliferative Capacity and Lifespan of Cells

To demonstrate the effectiveness of the present method for extending the proliferative capacity and lifespan of cells, human fibroblast cells lines (either WI38 at Population Doubling (PDL) 23 or BJ cells at PDL 71) are thawed and plated on T75 flasks and allowed to grow in normal medium (DMEM/M199 plus 10% bovine calf serum) for about a week, at which time the cells are confluent, and the cultures are therefor ready to be subdivided. At the time of subdivision, the media is aspirated, and the 15 cells rinsed with phosphate buffer saline (PBS) and then trypsinized. The cells are counted with a Coulter counter and plated at a density of  $10^5$  cells per  $\text{cm}^2$  in 6-well tissue culture plates in DMEM/199 medium supplemented with 10% bovine calf serum and varying amounts (0.10 $\mu\text{M}$ , and 1mM: from a 100X stock 20 solution in DMEM/M199 medium) of a PARP inhibitor of Formula I as disclosed herein. This process is repeated every 7 days until the cell appear to stop dividing. The untreated (control) cells reach senescence and stop dividing after about 40 days in culture. Treatment of cells with 10  $\mu\text{M}$  3-AB appears to have 25 little or no effect in contrast to treatment with 100  $\mu\text{M}$  3-AB which appears lengthen the lifespan of the cells and treatment with 1 mM 3-AB which dramatically increases the lifespan and proliferative capacity of the cells. The cells treated with 1 mM 3-AB will still divide after 60 days in culture.

30

Example 16:      Neuroprotective Effects of Formula I on Chronic Constriction Injury (CCI) in Rats

Adult male Sprague-Dawley rats, 300-350 g, are anesthetized with intraperitoneal 50 mg/kg sodium pentobarbital. Nerve 35 ligation is performed by exposing one side of the rat's sciatic

nerves and dissecting a 5-7 mm-long nerve segment and closing with four loose ligatures at a 1.0-1.5-mm, followed by implanting of an intrathecal catheter and inserting of a gentamicin sulfate-flushed polyethylene (PE-10) tube into the  
5 subarachnoid space through an incision at the cisterna magna. The caudal end of the catheter is gently threaded to the lumbar enlargement and the rostral end is secured with dental cement to a screw embedded in the skull and the skin wound is closed with wound clips.

10 Thermal hyperalgesia to radiant heat is assessed by using a paw-withdrawal test. The rat is placed in a plastic cylinder on a 3-mm thick glass plate with a radiant heat source from a projection bulb placed directly under the plantar surface of the rat's hindpaw. The paw-withdrawal latency is defined as the  
15 time elapsed from the onset of radiant heat stimulation to withdrawal of the rat's hindpaw.

Mechanical hyperalgesia is assessed by placing the rat in a cage with a bottom made of perforated metal sheet with many small square holes. Duration of paw-withdrawal is recorded  
20 after pricking the mid-plantar surface of the rat's hindpaw with the tip of a safety pin inserted through the cage bottom.

Mechano-allodynia is assessed by placing a rat in a cage similar to the previous test, and applying von Frey filaments in ascending order of bending force ranging from 0.07 to 76 g  
25 to the mid-plantar surface of the rat's hindpaw. A von Frey filament is applied perpendicular to the skin and depressed slowly until it bends. A threshold force of response is defined as the first filament in the series to evoke at least one clear paw-withdrawal out of five applications.


30 Dark neurons are observed bilaterally within the spinal cord dorsal horn, particularly in laminae I-II, of rats 8 days after unilateral sciatic nerve ligation as compared with sham operated rats. Various doses of differing compounds of Formula I are tested in this model and show that the Formula I compounds

reduce both incidence of dark neurons and neuropathic pain behavior in CCI rats.

The invention being thus described, it will be obvious that the same may be varied in many ways. Such variations are not 5 to be regarded as a departure from the spirit and scope of the invention, and all such modifications are intended to be included within the scope of the following claims.

We claim:

1. A compound of formula I:



5 or a pharmaceutically acceptable salt, hydrate, ester, solvate, prodrug, metabolite, stereoisomer, or mixtures thereof, wherein:

R¹ is lower alkyl, lower alkenyl or lower alkynyl;

R⁹, when present, is hydrogen or lower alkyl;

10 Y represents the atoms necessary to form a fused 5- to 6-membered ring that is aromatic or nonaromatic and carbocyclic or heterocyclic;

Z is (i) -CHR²CHR³- where R² and R³ are independently hydrogen, alkyl, aryl or aralkyl;

15 (ii) -R⁶C=CR³- where R⁶ and R³ are independently hydrogen, lower alkyl, aryl, aralkyl, chlorine, bromine or -NR⁷R⁸, where R⁷ and R⁸ are independently hydrogen or lower alkyl, or, R⁶ and R³, taken together, form a fused 5- to 6-membered ring that is aromatic or nonaromatic and carbocyclic or heterocyclic;

20 (iii) -R²C=N-;

(iv) -CR²(OH)-NR⁷-; or

(v) -C(O)-NR⁷-;

25 provided that when R¹ is methyl, R⁹ is absent, and R⁶ and R³ form a 6-membered, carbocyclic unsaturated ring, Y is aromatic and/or heterocyclic.

2. The compound of claim 1, wherein Y has at least one site of unsaturation.

3. The compound of claim 1, wherein Y represents the atoms necessary to form a 5- to 6-membered carbocyclic ring.

4. The compound of claim 3, wherein Y is aromatic.

5

5. The compound of claim 3, wherein Y represents the atoms necessary to form a fused benzene ring.

6. The compound of claim 3, wherein Y is non-aromatic.

10

7. The compound of claim 1, wherein Y represents the atoms necessary to form a 5- to 6-membered N-containing ring.

8. The compound of claim 7, wherein Y is aromatic.


15

9. The compound of claim 7, wherein Y is non-aromatic.


10. The compound of claim 1, wherein said compound has an isoquinoline, a phenanthridine, a phthalazine or a 20 quinazoline nucleus.

11. The compound of claim 10, wherein said compound has an isoquinoline nucleus.


25 12. The compound of claim 1, wherein the compound is selected from the group consisting of




I



II



III and




IV.

5        13. The compound of claim 1, wherein said compound has  
 an IC<sub>50</sub> of 100 µM or lower for inhibiting poly(ADP-ribose)  
 polymerase in vitro.

10      14. The compound of claim 1, wherein said compound has  
 an IC<sub>50</sub> of 25 µM or lower for inhibiting poly(ADP-ribose)  
 polymerase in vitro.

15      15. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound of formula I:



or a pharmaceutically acceptable salt, hydrate, ester,  
 solvate, prodrug, metabolite, stereoisomer, or mixtures  
 thereof, wherein:

R¹ is lower alkyl, lower alkenyl or lower alkynyl;

20      R⁹, when present, is hydrogen or lower alkyl;

Y represents the atoms necessary to form a fused 5- to  
 6-membered ring that is aromatic or nonaromatic and  
 carbocyclic or heterocyclic;

Z is (i) -CHR²CHR³- where R² and R³ are independently

25      hydrogen, alkyl, aryl or aralkyl;

(ii) -R⁶C=CR³- where R⁶ and R³ are independently

hydrogen, lower alkyl, aryl, aralkyl, chlorine, bromine or  $-NR^7R^8$ , where  $R^7$  and  $R^8$  are independently hydrogen or lower alkyl, or,  $R^6$  and  $R^3$ , taken together, form a fused 5- to 6-membered ring that is aromatic or nonaromatic and carbocyclic or heterocyclic;

- (iii)  $-R^2C=N-$ ;

(iv)  $-CR^2(OH)-NR^7-$ ; or

(v)  $-C(O)-NR^7-$ ;

10 provided that when  $R^1$  is methyl,  $R^9$  is absent, and  $R^6$  and  $R^3$  form a 6-membered, carbocyclic unsaturated ring, Y is aromatic and/or heterocyclic.

16. The composition of claim 15, wherein Y has at least  
15 one site of unsaturation.

17. The composition of claim 15, wherein Y represents the atoms necessary to form a fused benzene ring.

20        18. The composition of claim 15, wherein said compound  
has an isoquinoline, a phenanthridine, a phthalazine or a  
quinazoline nucleus.

19. The composition of claim 18, wherein said compound  
25 has an isoquinoline nucleus.

20. The composition of claim 15, wherein Y represents the atoms necessary to form a 5- to 6-membered carbocyclic ring.

- 30

21. The composition of claim 20, wherein Y is aromatic.


22. The composition of claim 20, wherein Y is non-aromatic.

23. The composition of claim 15, wherein Y represents the atoms necessary to form a 5- to 6- membered N-containing heterocyclic ring.


5 24. The composition of claim 23, wherein Y is aromatic.

25. The composition of claim 23, wherein Y is non-aromatic.


10 26. The composition of claim 15, wherein the compound is selected from the group consisting of



I



II



III and



IV.

15

27. The composition of claim 15, wherein said compound has an IC<sub>50</sub> of 100 µM or lower for inhibiting poly(ADP-ribose) polymerase in vitro.

28. The composition of claim 15, wherein said agent has an IC<sub>50</sub> of 25 µM or lower for inhibiting poly(ADP-ribose) polymerase in vitro.

25

29. The composition of claim 15, wherein said

composition is administered as a sterile solution, suspension or emulsion, in a single or divided dose.

30. The composition of claim 15, wherein said  
5 composition is administered as a solid implant capable of  
releasing the compound over a prolonged period of time.


31. The composition of claim 15, wherein said  
composition is administered as a capsule or tablet containing  
10 a single or divided dose of said compound.

32. The composition of claim 15, wherein the carrier  
comprises a biodegradable polymer.

15 33. The composition of claim 34, wherein the  
composition is a solid implant.

34. The composition of claim 34, wherein the  
biodegradable polymer releases the compound of formula I over  
20 a prolonged period of time.

35. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound of formula I:



25 or a pharmaceutically acceptable salt, hydrate, ester,  
solvate, prodrug, metabolite, stereoisomer, or mixtures  
thereof, wherein the compound of formula I is present in an  
amount that is effective for inhibiting PARP activity; and  
wherein:

30 R<sup>1</sup> is lower alkyl, lower alkenyl or lower alkynyl;  
R<sup>9</sup>, when present, is hydrogen or lower alkyl;

Y represents the atoms necessary to form a fused 5- to 6-membered ring that is aromatic or nonaromatic and carbocyclic or heterocyclic;

Z is (i) -CHR<sup>2</sup>CHR<sup>3</sup>- where R<sup>2</sup> and R<sup>3</sup> are independently hydrogen, alkyl, aryl or aralkyl;  
5 (ii) -R<sup>6</sup>C=CR<sup>3</sup>- where R<sup>6</sup> and R<sup>3</sup> are independently hydrogen, lower alkyl, aryl, aralkyl, chlorine, bromine or -NR<sup>7</sup>R<sup>8</sup>, where R<sup>7</sup> and R<sup>8</sup> are independently hydrogen or lower alkyl, or, R<sup>6</sup> and R<sup>3</sup>, taken together, form a fused 5- to 6-membered ring that is aromatic or nonaromatic and carbocyclic or heterocyclic;  
10 (iii) -R<sup>2</sup>C=N-;  
(iv) -CR<sup>2</sup>(OH)-NR<sup>7</sup>-; or  
15 (v) -C(O)-NR<sup>7</sup>-;


provided that when R<sup>1</sup> is methyl, R<sup>9</sup> is absent, and R<sup>6</sup> and R<sup>3</sup> form a 6-membered, carbocyclic unsaturated ring, Y is aromatic and/or heterocyclic.

20 36. The pharmaceutical composition of claim 35 for treatment or prevention of diseases or conditions selected from the group consisting of tissue damage resulting from cell damage or death due to necrosis or apoptosis, neuronal mediated tissue damage or diseases, neural tissue damage  
25 resulting from ischemia and reperfusion injury, neurological disorders and neurodegenerative diseases, vascular stroke, cardiovascular disorders, age-related macular degeneration, AIDS and other immune senescence diseases, arthritis, atherosclerosis, cachexia, cancer, degenerative diseases of  
30 skeletal muscle involving replicative senescence, diabetes, head trauma, immune senescence, inflammatory bowel disorders, muscular dystrophy, osteoarthritis, osteoporosis, chronic pain, acute pain, neuropathic pain, nervous insult, peripheral nerve injury, renal failure, retinal ischemia,

septic shock, and skin aging, diseases or disorders relating to lifespan or proliferative capacity of cells, and diseases or disease conditions induced or exacerbated by cellular senescence.

5

37. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound of formula I:



or a pharmaceutically acceptable salt, hydrate, ester,  
10 solvate, prodrug, metabolite, stereoisomer, or mixtures  
thereof, wherein the compound of formula I is present in an  
amount that is effective for effecting a neuronal activity;  
and wherein:

R¹ is lower alkyl, lower alkenyl or lower alkynyl;  
15 R⁹, when present, is hydrogen or lower alkyl;  
Y represents the atoms necessary to form a fused 5- to  
6-membered ring that is aromatic or nonaromatic and  
carbocyclic or heterocyclic;  
Z is (i) -CHR²CHR³- where R² and R³ are independently  
20 hydrogen, alkyl, aryl or aralkyl;  
(ii) -R⁶C=CR³- where R⁶ and R³ are independently  
hydrogen, lower alkyl, aryl, aralkyl, chlorine,  
bromine or -NR⁷R⁸, where R⁷ and R⁸ are independently  
hydrogen or lower alkyl, or, R⁶ and R³, taken  
25 together, form a fused 5- to 6-membered ring that  
is aromatic or nonaromatic and carbocyclic or  
heterocyclic;  
(iii) -R²C=N-;  
(iv) -CR²(OH)-NR⁷-; or  
30 (v) -C(O)-NR⁷-;

provided that when R¹ is methyl, R⁹ is absent, and R⁶ and R³

form a 6-membered, carbocyclic unsaturated ring, Y is aromatic and/or heterocyclic.

38. The composition of claim 37, wherein the neuronal  
5 activity is selected from the group consisting of stimulation  
of damaged neurons, promotion of neuronal regeneration,  
prevention of neurodegeneration, and treatment of a  
neurological disorder.


10 39. The composition of claim 38, wherein said damaged  
neurons result from cerebral ischemia or reperfusion injury.

40. The composition of claim 38, wherein the  
neurological disorder is selected from the group consisting  
15 of peripheral neuropathy caused by physical injury or disease  
state, traumatic brain injury, physical damage to the spinal  
cord, stroke associated with brain damage, demyelinating  
disease and neurological disorder relating to  
neurodegeneration.

20

41. The composition of claim 40, wherein the  
neurological disorder relating to neurodegeneration is  
selected from the group consisting of Alzheimer's Disease,  
Parkinson's Disease, Huntington's Disease and amyotrophic  
25 lateral sclerosis.

42. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound of formula I:



30 or a pharmaceutically acceptable salt, hydrate, ester,  
solvate, prodrug, metabolite, stereoisomer, or mixtures

thereof, wherein the compound of formula I is present in an amount that is effective for treating arthritis; and wherein:

R<sup>1</sup> is lower alkyl, lower alkenyl or lower alkynyl;

R<sup>9</sup>, when present, is hydrogen or lower alkyl;

Y represents the atoms necessary to form a fused 5- to 6-membered ring that is aromatic or nonaromatic and carbocyclic or heterocyclic;

Z is (i) -CHR<sup>2</sup>CHR<sup>3</sup>- where R<sup>2</sup> and R<sup>3</sup> are independently hydrogen, alkyl, aryl or aralkyl;

(ii) -R<sup>6</sup>C=CR<sup>3</sup>- where R<sup>6</sup> and R<sup>3</sup> are independently hydrogen, lower alkyl, aryl, aralkyl, chlorine, bromine or -NR<sup>7</sup>R<sup>8</sup>, where R<sup>7</sup> and R<sup>8</sup> are independently hydrogen or lower alkyl, or, R<sup>6</sup> and R<sup>3</sup>, taken together, form a fused 5- to 6-membered ring that is aromatic or nonaromatic and carbocyclic or heterocyclic;


(iii) -R<sup>2</sup>C=N-;

(iv) -CR<sup>2</sup>(OH)-NR<sup>7</sup>-; or

(v) -C(O)-NR<sup>7</sup>-;

provided that when R<sup>1</sup> is methyl, R<sup>9</sup> is absent, and R<sup>6</sup> and R<sup>3</sup> form a 6-membered, carbocyclic unsaturated ring, Y is aromatic and/or heterocyclic.

43. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound of formula I:



or a pharmaceutically acceptable salt, hydrate, ester, solvate, prodrug, metabolite, stereoisomer, or mixtures thereof, wherein the compound of formula I is present in an amount that is effective for treating diabetes; and wherein:

R<sup>1</sup> is lower alkyl, lower alkenyl or lower alkynyl;


$R^9$ , when present, is hydrogen or lower alkyl;  
 $Y$  represents the atoms necessary to form a fused 5- to  
 6-membered ring that is aromatic or nonaromatic and  
 carbocyclic or heterocyclic;

- 5        Z is (i)  $-\text{CHR}^2\text{CHR}^3-$  where  $\text{R}^2$  and  $\text{R}^3$  are independently  
 hydrogen, alkyl, aryl or aralkyl;  
 (ii)  $-\text{R}^6\text{C}=\text{CR}^3-$  where  $\text{R}^6$  and  $\text{R}^3$  are independently  
 hydrogen, lower alkyl, aryl, aralkyl, chlorine,  
 bromine or  $-\text{NR}^7\text{R}^8$ , where  $\text{R}^7$  and  $\text{R}^8$  are independently  
 10      hydrogen or lower alkyl, or,  $\text{R}^6$  and  $\text{R}^3$ , taken  
 together, form a fused 5- to 6-membered ring that  
 is aromatic or nonaromatic and carbocyclic or  
 heterocyclic;  
 (iii)  $-\text{R}^2\text{C}=\text{N}-$ ;  
 15      (iv)  $-\text{CR}^2(\text{OH})-\text{NR}^7-$ ; or  
 (v)  $-\text{C}(\text{O})-\text{NR}^7-$ ;

provided that when  $\text{R}^1$  is methyl,  $\text{R}^9$  is absent, and  $\text{R}^6$  and  $\text{R}^3$   
 form a 6-membered, carbocyclic unsaturated ring,  $Y$  is  
 aromatic and/or heterocyclic.

20

44. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound of formula I:



or a pharmaceutically acceptable salt, hydrate, ester,  
 25      solvate, prodrug, metabolite, stereoisomer, or mixtures  
 thereof, wherein the compound of formula I is present in an  
 amount that is effective for treating an inflammatory bowel  
 disorder; and wherein:

- 30       $\text{R}^1$  is lower alkyl, lower alkenyl or lower alkynyl;  
 $\text{R}^9$ , when present, is hydrogen or lower alkyl;  
 $Y$  represents the atoms necessary to form a fused 5- to

6-membered ring that is aromatic or nonaromatic and carbocyclic or heterocyclic;

$Z$  is (i)  $-\text{CHR}^2\text{CHR}^3-$  where  $R^2$  and  $R^3$  are independently

hydrogen, alkyl, aryl or aralkyl;

5

(ii)  $-\text{R}^6\text{C}=\text{CR}^3-$  where  $R^6$  and  $R^3$  are independently hydrogen, lower alkyl, aryl, aralkyl, chlorine, bromine or  $-\text{NR}^7\text{R}^8$ , where  $R^7$  and  $R^8$  are independently hydrogen or lower alkyl, or,  $R^6$  and  $R^3$ , taken together, form a fused 5- to 6-membered ring that

10

is aromatic or nonaromatic and carbocyclic or heterocyclic;

(iii)  $-\text{R}^2\text{C}=\text{N}-$ ;

(iv)  $-\text{CR}^2(\text{OH})-\text{NR}^7-$ ; or


(v)  $-\text{C}(\text{O})-\text{NR}^7-$ ;

15 provided that when  $R^1$  is methyl,  $R^9$  is absent, and  $R^6$  and  $R^3$  form a 6-membered, carbocyclic unsaturated ring,  $Y$  is aromatic and/or heterocyclic.

45. The composition of claim 44, wherein the bowel disorder is colitis.

46. The composition of claim 44, wherein the bowel disorder is Crohn's disease.

25 47. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound of formula I:



or a pharmaceutically acceptable salt, hydrate, ester, solvate, prodrug, metabolite, stereoisomer, or mixtures

30 thereof, wherein the compound of formula I is present in an amount that is effective for treating a cardiovascular

disorder; and wherein:

R<sup>1</sup> is lower alkyl, lower alkenyl or lower alkynyl;

R<sup>9</sup>, when present, is hydrogen or lower alkyl;

Y represents the atoms necessary to form a fused 5- to  
5  
6-membered ring that is aromatic or nonaromatic and  
carbocyclic or heterocyclic;

Z is (i) -CHR<sup>2</sup>CHR<sup>3</sup>- where R<sup>2</sup> and R<sup>3</sup> are independently  
hydrogen, alkyl, aryl or aralkyl;

10 (ii) -R<sup>6</sup>C=CR<sup>3</sup>- where R<sup>6</sup> and R<sup>3</sup> are independently  
hydrogen, lower alkyl, aryl, aralkyl, chlorine,  
bromine or -NR<sup>7</sup>R<sup>8</sup>, where R<sup>7</sup> and R<sup>8</sup> are independently  
hydrogen or lower alkyl, or, R<sup>6</sup> and R<sup>3</sup>, taken  
together, form a fused 5- to 6-membered ring that  
is aromatic or nonaromatic and carbocyclic or  
15 heterocyclic;

(iii) -R<sup>2</sup>C=N-;

(iv) -CR<sup>2</sup>(OH)-NR<sup>7</sup>-; or


(v) -C(O)-NR<sup>7</sup>-;

provided that when R<sup>1</sup> is methyl, R<sup>9</sup> is absent, and R<sup>6</sup> and R<sup>3</sup>  
20 form a 6-membered, carbocyclic unsaturated ring, Y is  
aromatic and/or heterocyclic.

48. The composition of claim 47, wherein the  
cardiovascular disorder is coronary artery disease,  
25 myocardial infarction, angina pectoris, cardiogenic shock and  
cardiovascular tissue damage.

49. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound of formula I:

30




or a pharmaceutically acceptable salt, hydrate, ester,

solvate, prodrug, metabolite, stereoisomer, or mixtures thereof, wherein the compound of formula I is present in an amount that is effective for treating septic shock; and wherein:

- 5      R<sup>1</sup> is lower alkyl, lower alkenyl or lower alkynyl;  
R<sup>9</sup>, when present, is hydrogen or lower alkyl;  
Y represents the atoms necessary to form a fused 5- to  
6-membered ring that is aromatic or nonaromatic and  
carbocyclic or heterocyclic;
- 10     Z is (i) -CHR<sup>2</sup>CHR<sup>3</sup>- where R<sup>2</sup> and R<sup>3</sup> are independently  
hydrogen, alkyl, aryl or aralkyl;  
(ii) -R<sup>6</sup>C=CR<sup>3</sup>- where R<sup>6</sup> and R<sup>3</sup> are independently  
hydrogen, lower alkyl, aryl, aralkyl, chlorine,  
bromine or -NR<sup>7</sup>R<sup>8</sup>, where R<sup>7</sup> and R<sup>8</sup> are independently  
hydrogen or lower alkyl, or, R<sup>6</sup> and R<sup>3</sup>, taken  
together, form a fused 5- to 6-membered ring that  
is aromatic or nonaromatic and carbocyclic or  
heterocyclic;  
(iii) -R<sup>2</sup>C=N-;  
20     (iv) -CR<sup>2</sup>(OH)-NR<sup>7</sup>-; or  
(v) -C(O)-NR<sup>7</sup>-;
- 15     provided that when R<sup>1</sup> is methyl, R<sup>9</sup> is absent, and R<sup>6</sup> and R<sup>3</sup>  
form a 6-membered, carbocyclic unsaturated ring, Y is  
aromatic and/or heterocyclic.
- 25

50. The composition of claim 49, wherein the type of septic shock is endotoxic shock.

51. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound of formula I:



or a pharmaceutically acceptable salt, hydrate, ester, solvate, prodrug, metabolite, stereoisomer, or mixtures thereof, wherein the compound of formula I is present in an amount that is effective for treating cancer; and wherein:

- 5        R<sup>1</sup> is lower alkyl, lower alkenyl or lower alkynyl;  
R<sup>9</sup>, when present, is hydrogen or lower alkyl;  
Y represents the atoms necessary to form a fused 5- to  
6-membered ring that is aromatic or nonaromatic and  
carbocyclic or heterocyclic;
- 10      Z is (i) -CHR<sup>2</sup>CHR<sup>3</sup>- where R<sup>2</sup> and R<sup>3</sup> are independently  
hydrogen, alkyl, aryl or aralkyl;  
(ii) -R<sup>6</sup>C=CR<sup>3</sup>- where R<sup>6</sup> and R<sup>3</sup> are independently  
hydrogen, lower alkyl, aryl, aralkyl, chlorine,  
bromine or -NR<sup>7</sup>R<sup>8</sup>, where R<sup>7</sup> and R<sup>8</sup> are independently  
15      hydrogen or lower alkyl, or, R<sup>6</sup> and R<sup>3</sup>, taken  
together, form a fused 5- to 6-membered ring that  
is aromatic or nonaromatic and carbocyclic or  
heterocyclic;  
(iii) -R<sup>2</sup>C=N-;  
20      (iv) -CR<sup>2</sup>(OH)-NR<sup>7</sup>-; or  
(v) -C(O)-NR<sup>7</sup>-;

provided that when R<sup>1</sup> is methyl, R<sup>9</sup> is absent, and R<sup>6</sup> and R<sup>3</sup>  
form a 6-membered, carbocyclic unsaturated ring, Y is  
aromatic and/or heterocyclic.

25

52. The composition of claim 51, wherein the cancer is selected from the group consisting of ACTH-producing tumors, acute lymphocytic leukemia, acute nonlymphocytic leukemia, cancer of the adrenal cortex, bladder cancer, brain cancer, breast cancer, cervical cancer, chronic lymphocytic leukemia, chronic myelocytic leukemia, colorectal cancer, cutaneous T-cell lymphoma, endometrial cancer, esophageal cancer, Ewing's sarcoma, gallbladder cancer, hairy cell leukemia, head & neck cancer, Hodgkin's lymphoma, Kaposi's sarcoma, kidney cancer,

liver cancer, lung cancer (small and/or non-small cell), malignant peritoneal effusion, malignant pleural effusion, melanoma, mesothelioma, multiple myeloma, neuroblastoma, non-Hodgkin's lymphoma, osteosarcoma, ovarian cancer, ovary (germ cell) cancer, prostate cancer, pancreatic cancer, penile cancer, retinoblastoma, skin cancer, soft-tissue sarcoma, squamous cell carcinomas, stomach cancer, testicular cancer, thyroid cancer, trophoblastic neoplasms, uterine cancer, vaginal cancer, cancer of the vulva and Wilm's tumor.

10


53. The composition of claim 51, wherein the carrier comprises a biodegradable polymer.

15 54. The composition of claim 53, wherein the composition is a solid implant.

55. The composition of claim 53, wherein the biodegradable polymer releases the compound of formula I over a prolonged period of time.

20

56. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound of formula I:



or a pharmaceutically acceptable salt, hydrate, ester, solvate, prodrug, metabolite, stereoisomer, or mixtures thereof, wherein the compound of formula I is present in an amount that is effective for radiosensitizing tumor cells; and wherein:

30 R¹ is lower alkyl, lower alkenyl or lower alkynyl;  
R⁹, when present, is hydrogen or lower alkyl;  
Y represents the atoms necessary to form a fused 5- to

6-membered ring that is aromatic or nonaromatic and carbocyclic or heterocyclic;

Z is (i) -CHR<sup>2</sup>CHR<sup>3</sup>- where R<sup>2</sup> and R<sup>3</sup> are independently hydrogen, alkyl, aryl or aralkyl;

5 (ii) -R<sup>6</sup>C=CR<sup>3</sup>- where R<sup>6</sup> and R<sup>3</sup> are independently hydrogen, lower alkyl, aryl, aralkyl, chlorine, bromine or -NR<sup>7</sup>R<sup>8</sup>, where R<sup>7</sup> and R<sup>8</sup> are independently hydrogen or lower alkyl, or, R<sup>6</sup> and R<sup>3</sup>, taken together, form a fused 5- to 6-membered ring that is aromatic or nonaromatic and carbocyclic or heterocyclic;

(iii) -R<sup>2</sup>C=N-;

(iv) -CR<sup>2</sup>(OH)-NR<sup>7</sup>-; or

(v) -C(O)-NR<sup>7</sup>-;

15 provided that when R<sup>1</sup> is methyl, R<sup>9</sup> is absent, and R<sup>6</sup> and R<sup>3</sup> form a 6-membered, carbocyclic unsaturated ring, Y is aromatic and/or heterocyclic.

57. The composition of claim 56, wherein said tumor  
20 cells are selected from the group consisting of ACTH-producing tumors, acute lymphocytic leukemia, acute nonlymphocytic leukemia, cancer of the adrenal cortex, bladder cancer, brain cancer, breast cancer, cervical cancer, chronic lymphocytic leukemia, chronic myelocytic leukemia,  
25 colorectal cancer, cutaneous T-cell lymphoma, endometrial cancer, esophageal cancer, Ewing's sarcoma, gallbladder cancer, hairy cell leukemia, head & neck cancer, Hodgkin's lymphoma, Kaposi's sarcoma, kidney cancer, liver cancer, lung cancer (small and/or non-small cell), malignant peritoneal effusion, malignant pleural effusion, melanoma, mesothelioma,  
30 multiple myeloma, neuroblastoma, non-Hodgkin's lymphoma, osteosarcoma, ovarian cancer, ovary (germ cell) cancer, prostate cancer, pancreatic cancer, penile cancer, retinoblastoma, skin cancer, soft-tissue sarcoma, squamous


cell carcinomas, stomach cancer, testicular cancer, thyroid cancer, trophoblastic neoplasms, uterine cancer, vaginal cancer, cancer of the vulva and Wilm's tumor.

5        58. The composition of claim 56, wherein the carrier comprises a biodegradable polymer.

10      59. The composition of claim 58, wherein the composition is a solid implant.

15      60. The composition of claim 58, wherein the biodegradable polymer releases the compound of formula I over a prolonged period of time.

20      61. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound of formula I:



25      or a pharmaceutically acceptable salt, hydrate, ester, solvate, prodrug, metabolite, stereoisomer, or mixtures thereof, wherein the compound of formula I is present in an amount that is effective for extending or increasing the lifespan or proliferative capacity of cells; and wherein:

R¹ is lower alkyl, lower alkenyl or lower alkynyl;

R⁹, when present, is hydrogen or lower alkyl;

Y represents the atoms necessary to form a fused 5- to 6-membered ring that is aromatic or nonaromatic and carbocyclic or heterocyclic;

Z is (i) -CHR²CHR³- where R² and R³ are independently hydrogen, alkyl, aryl or aralkyl;

30      (ii) -R⁶C=CR³- where R⁶ and R³ are independently hydrogen, lower alkyl, aryl, aralkyl, chlorine,

bromine or  $-NR^7R^8$ , where  $R^7$  and  $R^8$  are independently hydrogen or lower alkyl, or,  $R^6$  and  $R^3$ , taken together, form a fused 5- to 6-membered ring that is aromatic or nonaromatic and carbocyclic or heterocyclic;


5

(iii)  $-R^2C=N-$ ;(iv)  $-CR^2(OH)-NR^7-$ ; or(v)  $-C(O)-NR^7-$ ;

provided that when  $R^1$  is methyl,  $R^9$  is absent, and  $R^6$  and  $R^3$  10 form a 6-membered, carbocyclic unsaturated ring,  $Y$  is aromatic and/or heterocyclic.

62. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound of formula I:

15



or a pharmaceutically acceptable salt, hydrate, ester, solvate, prodrug, metabolite, stereoisomer, or mixtures thereof, wherein the compound of formula I is present in an amount that is effective for altering the gene expression of 20 senescent cells; and wherein:

$R^1$  is lower alkyl, lower alkenyl or lower alkynyl;

$R^9$ , when present, is hydrogen or lower alkyl;

$Y$  represents the atoms necessary to form a fused 5- to 6-membered ring that is aromatic or nonaromatic and carbocyclic or heterocyclic;

25

$Z$  is (i)  $-CHR^2CHR^3-$  where  $R^2$  and  $R^3$  are independently hydrogen, alkyl, aryl or aralkyl;

(ii)  $-R^6C=CR^3-$  where  $R^6$  and  $R^3$  are independently hydrogen, lower alkyl, aryl, aralkyl, chlorine,

30

bromine or  $-NR^7R^8$ , where  $R^7$  and  $R^8$  are independently hydrogen or lower alkyl, or,  $R^6$  and  $R^3$ , taken

together, form a fused 5- to 6-membered ring that is aromatic or nonaromatic and carbocyclic or heterocyclic;


(iii)  $-R^2C=N-$ ;

5 (iv)  $-CR^2(OH)-NR^7-$ ; or  
(v)  $-C(O)-NR^7-$ ;

provided that when  $R^1$  is methyl,  $R^9$  is absent, and  $R^6$  and  $R^3$  form a 6-membered, carbocyclic unsaturated ring,  $Y$  is aromatic and/or heterocyclic.

10

63. A method of inhibiting PARP activity comprising administering a compound of formula I:



15 or a pharmaceutically acceptable salt, hydrate, ester, solvate, prodrug, metabolite, stereoisomer, or mixtures thereof, wherein:

$R^1$  is lower alkyl, lower alkenyl or lower alkynyl;

$R^9$ , when present, is hydrogen or lower alkyl;

20  $Y$  represents the atoms necessary to form a fused 5- to 6-membered ring that is aromatic or nonaromatic and carbocyclic or heterocyclic;

$Z$  is (i)  $-CHR^2CHR^3-$  where  $R^2$  and  $R^3$  are independently

hydrogen, alkyl, aryl or aralkyl;

(ii)  $-R^6C=CR^3-$  where  $R^6$  and  $R^3$  are independently

25 hydrogen, lower alkyl, aryl, aralkyl, chlorine, bromine or  $-NR^7R^8$ , where  $R^7$  and  $R^8$  are independently hydrogen or lower alkyl, or,  $R^6$  and  $R^3$ , taken together, form a fused 5- to 6-membered ring that is aromatic or nonaromatic and carbocyclic or heterocyclic;

30 (iii)  $-R^2C=N-$ ;

(iv)  $-\text{CR}^2(\text{OH})-\text{NR}^7-$ ; or

(v)  $-\text{C}(\text{O})-\text{NR}^7-$ ;

provided that when  $\text{R}^1$  is methyl,  $\text{R}^9$  is absent, and  $\text{R}^6$  and  $\text{R}^3$  form a 6-membered, carbocyclic unsaturated ring,  $\text{Y}$  is  
5 aromatic and/or heterocyclic.

64. The method of claim 63, wherein  $\text{Y}$  has at least one site of unsaturation.

10 65. The method of claim 63, wherein  $\text{Y}$  represents the atoms necessary to form a fused benzene ring.

15 66. The method of claim 63, wherein said compound has an isoquinoline, a phenanthridine, a phthalazine, or a quinazoline nucleus.

67. The method of claim 66, wherein said compound has an isoquinoline nucleus.

20 68. The method of claim 63, wherein  $\text{Y}$  represents the atoms necessary to form a 5- to 6-membered carbocyclic ring.

69. The method of claim 68, wherein  $\text{Y}$  is aromatic.

25 70. The method of claim 68, wherein  $\text{Y}$  is non-aromatic.


71. The method of claim 63, wherein  $\text{Y}$  represents the atoms necessary to form a 5- to 6- membered N-containing heterocyclic ring.

30


72. The method of claim 71, wherein  $\text{Y}$  is aromatic.

73. The method of claim 71, wherein  $\text{Y}$  is non-aromatic.


74. The method of claim 63, wherein the compound is selected from the group consisting of




I



II



III



IV

5

and


10 75. The method of claim 63, wherein said compound has an IC<sub>50</sub> of 100 μM or lower for inhibiting poly(ADP-ribose) polymerase in vitro.

15 76. The method of claim 63, wherein said compound has an IC<sub>50</sub> of 25 μM or lower for inhibiting poly(ADP-ribose) polymerase in vitro.

20 77. The pharmaceutical composition of claim 63 for treatment or prevention of diseases or conditions selected from the group consisting of tissue damage resulting from cell damage or death due to necrosis or apoptosis, neuronal mediated tissue damage or diseases, neural tissue damage resulting from ischemia and reperfusion injury, neurological disorders and neurodegenerative diseases, vascular stroke, cardiovascular disorders, age-related macular degeneration, AIDS and other immune senescence diseases, arthritis,

atherosclerosis, cachexia, cancer, degenerative diseases of skeletal muscle involving replicative senescence, diabetes, head trauma, immune senescence, inflammatory bowel disorders, muscular dystrophy, osteoarthritis, osteoporosis, chronic 5 pain, acute pain, neuropathic pain, nervous insult, peripheral nerve injury, renal failure, retinal ischemia, septic shock, and skin aging, diseases or disorders relating to lifespan or proliferative capacity of cells, and diseases or disease conditions induced or exacerbated by cellular 10 senescence.

78. A method of effecting a neuronal activity not mediated by NMDA toxicity in an animal comprising administering to said animal an effective amount of a 15 compound of formula I:



or a pharmaceutically acceptable salt, hydrate, ester, solvate, prodrug, metabolite, stereoisomer, or mixtures thereof, wherein:

- 20      R<sup>1</sup> is lower alkyl, lower alkenyl or lower alkynyl; R<sup>9</sup>, when present, is hydrogen or lower alkyl;  
 Y represents the atoms necessary to form a fused 5- to 6-membered ring that is aromatic or nonaromatic and carbocyclic or heterocyclic;
- 25      Z is (i) -CHR<sup>2</sup>CHR<sup>3</sup>- where R<sup>2</sup> and R<sup>3</sup> are independently hydrogen, alkyl, aryl or aralkyl;  
 (ii) -R<sup>6</sup>C=CR<sup>3</sup>- where R<sup>6</sup> and R<sup>3</sup> are independently hydrogen, lower alkyl, aryl, aralkyl, chlorine, bromine or -NR<sup>7</sup>R<sup>8</sup>, where R<sup>7</sup> and R<sup>8</sup> are independently hydrogen or lower alkyl, or, R<sup>6</sup> and R<sup>3</sup>, taken 30 together, form a fused 5- to 6-membered ring that

is aromatic or nonaromatic and carbocyclic or heterocyclic;

(iii)  $-R^2C=N-$ ;

(iv)  $-CR^2(OH)-NR^7-$ ; or

5 (v)  $-C(O)-NR^7-$ ;

provided that when  $R^1$  is methyl,  $R^9$  is absent, and  $R^6$  and  $R^3$  form a 6-membered, carbocyclic unsaturated ring, Y is aromatic and/or heterocyclic.

10 79. The method of claim 78, wherein the neuronal activity is selected from the group consisting of stimulation of damaged neurons, promotion of neuronal regeneration, prevention of neurodegeneration, and treatment of a neurological disorder.

15

80. The method of claim 79, wherein said damaged neurons result from cerebral ischemia or reperfusion injury.


20 81. The method of claim 79, wherein the neurological disorder is selected from the group consisting of peripheral neuropathy caused by physical injury or disease state, traumatic brain injury, physical damage to the spinal cord, stroke associated with brain damage, demyelinating disease and neurological disorder relating to neurodegeneration.

25

82. The method of claim 81, wherein the neurological disorder relating to neurodegeneration is selected from the group consisting of Alzheimer's Disease, Parkinson's Disease, Huntington's Disease and amyotrophic lateral sclerosis.

30


83. A method of treating arthritis in an animal comprising administering to said animal an effective amount of a compound of formula I:



or a pharmaceutically acceptable salt, hydrate, ester, solvate, prodrug, metabolite, stereoisomer, or mixtures thereof, wherein:

- 5      R¹ is lower alkyl, lower alkenyl or lower alkynyl;
  - R⁹, when present, is hydrogen or lower alkyl;
  - Y represents the atoms necessary to form a fused 5- to 6-membered ring that is aromatic or nonaromatic and carbocyclic or heterocyclic;
  - 10     Z is (i) -CHR²CHR³- where R² and R³ are independently hydrogen, alkyl, aryl or aralkyl;
  - (ii) -R⁶C=CR³- where R⁶ and R³ are independently hydrogen, lower alkyl, aryl, aralkyl, chlorine, bromine or -NR⁷R⁸, where R⁷ and R⁸ are independently hydrogen or lower alkyl, or, R⁶ and R³, taken together, form a fused 5- to 6-membered ring that is aromatic or nonaromatic and carbocyclic or heterocyclic;
  - 15     (iii) -R²C=N-;
  - (iv) -CR²(OH)-NR⁷-; or
  - (v) -C(O)-NR⁷-;
- provided that when R¹ is methyl, R⁹ is absent, and R⁶ and R³ form a 6-membered, carbocyclic unsaturated ring, Y is aromatic and/or heterocyclic.

- 25
- 84. A method of treating diabetes in an animal comprising administering to said animal an effective amount of a compound of formula I:




or a pharmaceutically acceptable salt, hydrate, ester, solvate, prodrug, metabolite, stereoisomer, or mixtures thereof, wherein:

- 5       $R^1$  is lower alkyl, lower alkenyl or lower alkynyl;  
 $R^9$ , when present, is hydrogen or lower alkyl;  
 $Y$  represents the atoms necessary to form a fused 5- to 6-membered ring that is aromatic or nonaromatic and carbocyclic or heterocyclic;
- 10      $Z$  is (i)  $-CHR^2CHR^3-$  where  $R^2$  and  $R^3$  are independently hydrogen, alkyl, aryl or aralkyl;  
(ii)  $-R^6C=CR^3-$  where  $R^6$  and  $R^3$  are independently hydrogen, lower alkyl, aryl, aralkyl, chlorine, bromine or  $-NR^7R^8$ , where  $R^7$  and  $R^8$  are independently hydrogen or lower alkyl, or,  $R^6$  and  $R^3$ , taken together, form a fused 5- to 6-membered ring that is aromatic or nonaromatic and carbocyclic or heterocyclic;  
(iii)  $-R^2C=N-$ ;  
(iv)  $-CR^2(OH)-NR^7-$ ; or  
(v)  $-C(O)-NR^7-$ ;

provided that when  $R^1$  is methyl,  $R^9$  is absent, and  $R^6$  and  $R^3$  form a 6-membered, carbocyclic unsaturated ring,  $Y$  is aromatic and/or heterocyclic.

25

85. A method of treating an inflammatory bowel in an animal disorder comprising administering to said animal an effective amount of a compound of formula I:



or a pharmaceutically acceptable salt, hydrate, ester, solvate, prodrug, metabolite, stereoisomer, or mixtures thereof, wherein:

- 5       $R^1$  is lower alkyl, lower alkenyl or lower alkynyl;
- $R^9$ , when present, is hydrogen or lower alkyl;
- $Y$  represents the atoms necessary to form a fused 5- to 6-membered ring that is aromatic or nonaromatic and carbocyclic or heterocyclic;
- 10      $Z$  is (i)  $-CHR^2CHR^3-$  where  $R^2$  and  $R^3$  are independently hydrogen, alkyl, aryl or aralkyl;
- (ii)  $-R^6C=CR^3-$  where  $R^6$  and  $R^3$  are independently hydrogen, lower alkyl, aryl, aralkyl, chlorine, bromine or  $-NR^7R^8$ , where  $R^7$  and  $R^8$  are independently hydrogen or lower alkyl, or,  $R^6$  and  $R^3$ , taken together, form a fused 5- to 6-membered ring that is aromatic or nonaromatic and carbocyclic or heterocyclic;
- 15     (iii)  $-R^2C=N-$ ;
- (iv)  $-CR^2(OH)-NR^7-$ ; or
- (v)  $-C(O)-NR^7-$ ;


provided that when  $R^1$  is methyl,  $R^9$  is absent, and  $R^6$  and  $R^3$  form a 6-membered, carbocyclic unsaturated ring,  $Y$  is aromatic and/or heterocyclic.

25

86. The method of claim 85, wherein the bowel disorder is colitis.

87. The method of claim 85, wherein the bowel disorder  
30 is Crohn's disease.

88. A method of treating a cardiovascular disorder in an animal comprising administering to said animal an effective amount of a compound of formula I:



5 or a pharmaceutically acceptable salt, hydrate, ester, solvate, prodrug, metabolite, stereoisomer, or mixtures thereof, wherein:

R¹ is lower alkyl, lower alkenyl or lower alkynyl;

R⁹, when present, is hydrogen or lower alkyl;

10 Y represents the atoms necessary to form a fused 5- to 6-membered ring that is aromatic or nonaromatic and carbocyclic or heterocyclic;

Z is (i) -CHR²CHR³- where R² and R³ are independently hydrogen, alkyl, aryl or aralkyl;

15 (ii) -R⁶C=CR³- where R⁶ and R³ are independently hydrogen, lower alkyl, aryl, aralkyl, chlorine, bromine or -NR⁷R⁸, where R⁷ and R⁸ are independently hydrogen or lower alkyl, or, R⁶ and R³, taken together, form a fused 5- to 6-membered ring that

20 is aromatic or nonaromatic and carbocyclic or heterocyclic;

(iii) -R²C=N-;

(iv) -CR²(OH)-NR⁷-; or


(v) -C(O)-NR⁷-;

25 provided that when R¹ is methyl, R⁹ is absent, and R⁶ and R³ form a 6-membered, carbocyclic unsaturated ring, Y is aromatic and/or heterocyclic.

89. The method of claim 88, wherein the cardiovascular disorder is coronary artery disease, myocardial infarction, angina pectoris, cardiogenic shock and cardiovascular tissue

damage.

90. A method of treating septic shock in an animal comprising administering to said animal an effective amount  
5 of compound of formula I:



or a pharmaceutically acceptable salt, hydrate, ester, solvate, prodrug, metabolite, stereoisomer, or mixtures thereof, wherein:

10      R¹ is lower alkyl, lower alkenyl or lower alkynyl;  
 R⁹, when present, is hydrogen or lower alkyl;  
 Y represents the atoms necessary to form a fused 5- to  
 6-membered ring that is aromatic or nonaromatic and  
 carbocyclic or heterocyclic;  
 15     Z is (i) -CHR²CHR³- where R² and R³ are independently  
 hydrogen, alkyl, aryl or aralkyl;  
 (ii) -R⁶C=CR³- where R⁶ and R³ are independently  
 hydrogen, lower alkyl, aryl, aralkyl, chlorine,  
 bromine or -NR⁷R⁸, where R⁷ and R⁸ are independently  
 20     hydrogen or lower alkyl, or, R⁶ and R³, taken  
 together, form a fused 5- to 6-membered ring that  
 is aromatic or nonaromatic and carbocyclic or  
 heterocyclic;  
 (iii) -R²C=N-;  
 25     (iv) -CR²(OH)-NR⁷-; or  
 (v) -C(O)-NR⁷-;


provided that when R¹ is methyl, R⁹ is absent, and R⁶ and R³  
 form a 6-membered, carbocyclic unsaturated ring, Y is  
 aromatic and/or heterocyclic.

30

91. The method of claim 90, wherein the type of septic

shock is endotoxic shock.

92. A method of treating cancer in an animal comprising administering to said animal an effective amount of a compound of formula I:



or a pharmaceutically acceptable salt, hydrate, ester, solvate, prodrug, metabolite, stereoisomer, or mixtures thereof, wherein:

- 10      R¹ is lower alkyl, lower alkenyl or lower alkynyl;
- R⁹, when present, is hydrogen or lower alkyl;
- Y represents the atoms necessary to form a fused 5- to 6-membered ring that is aromatic or nonaromatic and carbocyclic or heterocyclic;
- 15      Z is (i) -CHR²CHR³- where R² and R³ are independently hydrogen, alkyl, aryl or aralkyl;
- (ii) -R⁶C=CR³- where R⁶ and R³ are independently hydrogen, lower alkyl, aryl, aralkyl, chlorine, bromine or -NR⁷R⁸, where R⁷ and R⁸ are independently hydrogen or lower alkyl, or, R⁶ and R³, taken together, form a fused 5- to 6-membered ring that is aromatic or nonaromatic and carbocyclic or heterocyclic;
- 20      (iii) -R²C=N-;
- (iv) -CR²(OH)-NR⁷-; or
- (v) -C(O)-NR⁷-;

provided that when R¹ is methyl, R⁹ is absent, and R⁶ and R³ form a 6-membered, carbocyclic unsaturated ring, Y is aromatic and/or heterocyclic.

30

93. The method of claim 92, wherein the cancer is

selected from the group consisting of ACTH-producing tumors, acute lymphocytic leukemia, acute nonlymphocytic leukemia, cancer of the adrenal cortex, bladder cancer, brain cancer, breast cancer, cervical cancer, chronic lymphocytic leukemia,

5 chronic myelocytic leukemia, colorectal cancer, cutaneous T-cell lymphoma, endometrial cancer, esophageal cancer, Ewing's sarcoma, gallbladder cancer, hairy cell leukemia, head & neck cancer, Hodgkin's lymphoma, Kaposi's sarcoma, kidney cancer, liver cancer, lung cancer (small and/or non-small cell),

10 malignant peritoneal effusion, malignant pleural effusion, melanoma, mesothelioma, multiple myeloma, neuroblastoma, non-Hodgkin's lymphoma, osteosarcoma, ovarian cancer, ovary (germ cell) cancer, prostate cancer, pancreatic cancer, penile cancer, retinoblastoma, skin cancer, soft-tissue sarcoma,


15 squamous cell carcinomas, stomach cancer, testicular cancer, thyroid cancer, trophoblastic neoplasms, uterine cancer, vaginal cancer, cancer of the vulva and Wilm's tumor.

94. The method of claim 92, wherein the carrier  
20 comprises a biodegradable polymer.

95. The method of claim 94, wherein the composition is  
a solid implant.

25 96. The method of claim 94, wherein the biodegradable polymer releases the compound of formula I over a prolonged period of time.

97. A method of radiosensitizing tumor cells comprising  
30 administering to said tumor cells an effective amount of a compound of formula I:



or a pharmaceutically acceptable salt, hydrate, ester, solvate, prodrug, metabolite, stereoisomer, or mixtures thereof, wherein:

- 5       $R^1$  is lower alkyl, lower alkenyl or lower alkynyl;
- $R^9$ , when present, is hydrogen or lower alkyl;
- Y represents the atoms necessary to form a fused 5- to 6-membered ring that is aromatic or nonaromatic and carbocyclic or heterocyclic;
- 10     Z is (i)  $-CHR^2CHR^3-$  where  $R^2$  and  $R^3$  are independently hydrogen, alkyl, aryl or aralkyl;
- (ii)  $-R^6C=CR^3-$  where  $R^6$  and  $R^3$  are independently hydrogen, lower alkyl, aryl, aralkyl, chlorine, bromine or  $-NR^7R^8$ , where  $R^7$  and  $R^8$  are independently hydrogen or lower alkyl, or,  $R^6$  and  $R^3$ , taken together, form a fused 5- to 6-membered ring that is aromatic or nonaromatic and carbocyclic or heterocyclic;
- 15     (iii)  $-R^2C=N-$ ;
- (iv)  $-CR^2(OH)-NR^7-$ ; or
- (v)  $-C(O)-NR^7-$ ;

provided that when  $R^1$  is methyl,  $R^9$  is absent, and  $R^6$  and  $R^3$  form a 6-membered, carbocyclic unsaturated ring, Y is aromatic and/or heterocyclic.

- 25     98. The method of claim 97, wherein said tumor cells are selected from the group consisting of ACTH-producing tumors, acute lymphocytic leukemia, acute nonlymphocytic leukemia, cancer of the adrenal cortex, bladder cancer, brain cancer, breast cancer, cervical cancer, chronic lymphocytic leukemia, chronic myelocytic leukemia, colorectal cancer,

cutaneous T-cell lymphoma, endometrial cancer, esophageal cancer, Ewing's sarcoma, gallbladder cancer, hairy cell leukemia, head & neck cancer, Hodgkin's lymphoma, Kaposi's sarcoma, kidney cancer, liver cancer, lung cancer (small and/or non-small cell), malignant peritoneal effusion, malignant pleural effusion, melanoma, mesothelioma, multiple myeloma, neuroblastoma, non-Hodgkin's lymphoma, osteosarcoma, ovarian cancer, ovary (germ cell) cancer, prostate cancer, pancreatic cancer, penile cancer, retinoblastoma, skin cancer, soft-tissue sarcoma, squamous cell carcinomas, stomach cancer, testicular cancer, thyroid cancer, trophoblastic neoplasms, uterine cancer, vaginal cancer, cancer of the vulva and Wilm's tumor.


15        99. The method of claim 97, wherein the carrier comprises a biodegradable polymer.

100. The method of claim 99, wherein the composition is a solid implant.

20

101. The method of claim 99, wherein the biodegradable polymer releases the compound of formula I over a prolonged period of time.

25        102. A method of extending or increasing the lifespan or proliferative capacity of cells comprising administering an effective amount of a compound of formula I:




30        or a pharmaceutically acceptable salt, hydrate, ester, solvate, prodrug, metabolite, stereoisomer, or mixtures thereof, wherein:

R<sup>1</sup> is lower alkyl, lower alkenyl or lower alkynyl;  
R<sup>9</sup>, when present, is hydrogen or lower alkyl;  
Y represents the atoms necessary to form a fused 5- to  
6-membered ring that is aromatic or nonaromatic and  
5 carbocyclic or heterocyclic;  
Z is (i) -CHR<sup>2</sup>CHR<sup>3</sup>- where R<sup>2</sup> and R<sup>3</sup> are independently  
hydrogen, alkyl, aryl or aralkyl;  
(ii) -R<sup>6</sup>C=CR<sup>3</sup>- where R<sup>6</sup> and R<sup>3</sup> are independently  
hydrogen, lower alkyl, aryl, aralkyl, chlorine,  
10 bromine or -NR<sup>7</sup>R<sup>8</sup>, where R<sup>7</sup> and R<sup>8</sup> are independently  
hydrogen or lower alkyl, or, R<sup>6</sup> and R<sup>3</sup>, taken  
together, form a fused 5- to 6-membered ring that  
is aromatic or nonaromatic and carbocyclic or  
heterocyclic;  
15 (iii) -R<sup>2</sup>C=N-;  
(iv) -CR<sup>2</sup>(OH)-NR<sup>7</sup>-; or  
(v) -C(O)-NR<sup>7</sup>-;  
provided that when R<sup>1</sup> is methyl, R<sup>9</sup> is absent, and R<sup>6</sup> and R<sup>3</sup>  
form a 6-membered, carbocyclic unsaturated ring, Y is  
20 aromatic and/or heterocyclic.

103. A method of altering gene expression of senescent  
cells comprising administering an effective amount of a  
compound of formula I:

25



or a pharmaceutically acceptable salt, hydrate, ester,  
solvate, prodrug, metabolite, stereoisomer, or mixtures  
thereof, wherein:

30

R<sup>1</sup> is lower alkyl, lower alkenyl or lower alkynyl;  
R<sup>9</sup>, when present, is hydrogen or lower alkyl;  
Y represents the atoms necessary to form a fused 5- to

6-membered ring that is aromatic or nonaromatic and carbocyclic or heterocyclic;

Z is (i)  $-\text{CHR}^2\text{CHR}^3-$  where  $\text{R}^2$  and  $\text{R}^3$  are independently hydrogen, alkyl, aryl or aralkyl;

5 (ii)  $-\text{R}^6\text{C=CR}^3-$  where  $\text{R}^6$  and  $\text{R}^3$  are independently hydrogen, lower alkyl, aryl, aralkyl, chlorine, bromine or  $-\text{NR}^7\text{R}^8$ , where  $\text{R}^7$  and  $\text{R}^8$  are independently hydrogen or lower alkyl, or,  $\text{R}^6$  and  $\text{R}^3$ , taken together, form a fused 5- to 6-membered ring that is aromatic or nonaromatic and carbocyclic or heterocyclic;

10 (iii)  $-\text{R}^2\text{C=N}-$ ;


(iv)  $-\text{CR}^2(\text{OH})-\text{NR}^7-$ ; or

(v)  $-\text{C}(\text{O})-\text{NR}^7-$ ;

15 provided that when  $\text{R}^1$  is methyl,  $\text{R}^9$  is absent, and  $\text{R}^6$  and  $\text{R}^3$  form a 6-membered, carbocyclic unsaturated ring, Y is aromatic and/or heterocyclic.

104. A process of making the compound of formula I:

20



or a pharmaceutically acceptable salt, hydrate, ester, solvate, prodrug, metabolite, stereoisomer, or mixtures thereof, wherein:

$\text{R}^1$  is lower alkyl, lower alkenyl or lower alkynyl;

25  $\text{R}^9$ , when present, is hydrogen or lower alkyl;

Y represents the atoms necessary to form a fused 5- to 6-membered ring that is aromatic or nonaromatic and carbocyclic or heterocyclic;

Z is (i)  $-\text{CHR}^2\text{CHR}^3-$  where  $\text{R}^2$  and  $\text{R}^3$  are independently hydrogen, alkyl, aryl or aralkyl;

30 (ii)  $-\text{R}^6\text{C=CR}^3-$  where  $\text{R}^6$  and  $\text{R}^3$  are independently

hydrogen, lower alkyl, aryl, aralkyl, chlorine, bromine or  $-NR^7R^8$ , where  $R^7$  and  $R^8$  are independently hydrogen or lower alkyl, or,  $R^6$  and  $R^3$ , taken together, form a fused 5- to 6-membered ring that is aromatic or nonaromatic and carbocyclic or heterocyclic;


5 (iii)  $-R^2C=N-$ ;

(iv)  $-CR^2(OH)-NR^7-$ ; or

(v)  $-C(O)-NR^7-$ ;

10 provided that when  $R^1$  is methyl,  $R^9$  is absent, and  $R^6$  and  $R^3$  form a 6-membered, carbocyclic unsaturated ring, Y is aromatic and/or heterocyclic; comprising


15 the step of contacting an intermediate having formula II:



II

with  $R-X$ , wherein X is a chloro, bromo or iodo moiety, and R is alkyl, alkenyl or alkynyl.


20 105. The process of claim 104 wherein formula II is prepared by contacting an intermediate having formula III:



III

with Lawesson's reagent or  $P_2S_5$ .

25 106. The process of claim 105 wherein an intermediate of formula III is prepared by contacting an intermediate having formula IV:



IV

with a Lewis base.

107. The process of claim 106 wherein an intermediate of  
5 formula IV is prepared by contacting an intermediate having  
formula V:



V


with the hydroxide of a Group I element.

10 108. The process of claim 107 wherein the Group I  
element is potassium.


109. The compounds, compositions, methods, and  
processes herein described.

1 / 2

FIG. 1



2 / 2

**FIG. 2**

# INTERNATIONAL SEARCH REPORT

International Application No  
PCT/US 98/18184

**A. CLASSIFICATION OF SUBJECT MATTER**

IPC 6 C07D217/24	C07D237/30	C07D221/16	C07D221/12	A61K31/47
C07D491/04	C07D495/04	C07D498/04	C07D513/04	C07D495/14
C07D498/14	C07D401/12	C07D487/04	//(C07D491/04,307:00,	

According to International Patent Classification (IPC) or to both national classification and IPC

**B. FIELDS SEARCHED**

Minimum documentation searched (classification system followed by classification symbols)  
IPC 6 C07D A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	EDWARD C. TAYLOR ET AL: "Nucleophilic displacement of primary amino groups via 1-substituted 4-tosylimidazoles" JOURNAL OF ORGANIC CHEMISTRY., vol. 47, no. 11, 1982, pages 2043-2047, XP002086818 EASTON US see page 2046  HARJIT SINGH ET AL: "Preparation of 2,3-dihydrothiazolo'2,3-a!isoquinolinium salts and their reactions with complex metal hydrides" JOURNAL OF THE CHEMICAL SOCIETY, PERKIN TRANSACTIONS 1., 1972, pages 1799-1803, XP002086819 LETCHWORTH GB see page 180o and 1801, compound 1  -/-/	1-5,10, 11
X		1-5,10, 11

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

\* Special categories of cited documents :

- \*A\* document defining the general state of the art which is not considered to be of particular relevance
- \*E\* earlier document but published on or after the international filing date
- \*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*O\* document referring to an oral disclosure, use, exhibition or other means
- \*P\* document published prior to the international filing date but later than the priority date claimed

- \*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- \*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- \*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- \*&\* document member of the same patent family

Date of the actual completion of the international search

7 December 1998

Date of mailing of the international search report

21/12/1998

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl.  
Fax: (+31-70) 340-3016

Authorized officer

Henry, J

# INTERNATIONAL SEARCH REPORT

Int'l Application No

PCT/US 98/18184

**A. CLASSIFICATION OF SUBJECT MATTER**  
 IPC 6 221:00), (C07D495/04, 333:00, 221:00)

According to International Patent Classification (IPC) or to both national classification and IPC

**B. FIELDS SEARCHED**

Minimum documentation searched (classification system followed by classification symbols)

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	ADRIEN ALBERT ET AL: "Ionisation constants of heterocyclic substances. Part III. Mercapto-derivatives of pyridine, quinoline and isoquinoline" JOURNAL OF THE CHEMICAL SOCIETY., 1959, pages 2384-2396, XP002086820 LETCHWORTH GB see page 2396 ---	1-5, 10, 11
X	D.A. PEAK ET AL: "Antituberculous compounds. Part X. Some reactions of quaternary compounds derived from NN-disubstituted thioamides" JOURNAL OF THE CHEMICAL SOCIETY., 1952, pages 4067-4075, XP002086821 LETCHWORTH GB see page 4071 ---	1-5, 10
		-/-

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

\* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

Date of mailing of the international search report

7 December 1998

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl.  
Fax: (+31-70) 340-3016

Authorized officer

Henry, J

## INTERNATIONAL SEARCH REPORT

International Application No  
PCT/US 98/18184

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	YOSHIKI HAMADA ET AL: "Studies on nitrogen-containing heterocyclic compounds.XXIV. Chemical reactivity of 1(or2)-cyano-1,2-dihydro(iso)quinolines and 1(or2)-cyano-1,2,3,4-tetrahydro(iso)quinolines" CHEMICAL AND PHARMACEUTICAL BULLETIN., vol. 26, no. 12, 1978, pages 3682-3694, XP002086822 TOKYO JP see page 3685, compound 5 ----	1-5,10, 11
X	CHEMICAL ABSTRACTS, vol. 96, no. 1, 4 January 1982 Columbus, Ohio, US; abstract no. 6539m, SINGH HARJIT ET AL: "Heterocycles inorganic synthesis.III.A facile synthesis of isoquinolinyl vinyl sulfides" page 592; XP002086826 see abstract & SYNTH.COMM., vol. 11, no. 8, 1981, pages 635-638, ----	1-5,10, 11
X	JAN BECHER ET AL: "Introduction of sulfur in compounds with reactive halogen atoms via the t-butylthiolate anion" PHOSPHORUS SULFUR, vol. 14, no. 1, 1982, pages 131-138, XP002086823 see page 134 ----	1-5,10, 11
X	M.LORA TAMAYO ET AL: "Thiocyanates in heterocyclic synthesis through nitrilium salts" TETRAHEDRON,SUPPL,8,PART1,1966, pages 305-312, XP002086824 OXFORD GB see pages 306,307,compouns V ----	1-5,10, 11
X	US 3 759 924 A (JEANMART C ET AL) 18 September 1973 see column 3, line 54 - line 64 ----	1-5,10, 11
X	EP 0 539 805 A (ASTA MEDICA AG) 5 May 1993 see claims ----	1-5,10
X	US 3 830 816 A (GITTO M ET AL) 20 August 1974 see example 1 ----	1-5,10, 11
		-/-

## INTERNATIONAL SEARCH REPORT

Intell. Int'l Application No  
PCT/US 98/18184

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	GB 1 379 111 A (ASPRO NICHOLAS LTD) 2 January 1975 see the whole document	1-5,10, 11
X	US 5 177 075 A (SUTO MARK J ET AL) 5 January 1993 cited in the application see the whole document	1-5,10, 11,15,36
X	US 3 247 212 A (FRANCIS JOHNSON ET AL) 19 April 1966 see the whole document	1-5,10, 11
A	M.J.SUTO ET AL: "Dihydroisoquinolinones:the design and synthesis of a new series of potent inhibitors of poly(ADP-ribose)polymerase" ANTI-CANCER DRUG DESIGN, vol. 7, 1991, pages 107-117, XP002086825 cited in the application see the whole document	1,15-103
A	GRIFFIN R J ET AL: "Novel potent inhibitors of the DNA repair enzyme poly(ADP-ribose)polymerase (PARP)" ANTI-CANCER DRUG DESIGN, vol. 10, no. 6, September 1995, pages 507-514, XP002065156 see the whole document	1,15-103
A	BANASIK M ET AL: "Specific inhibitors of poly(ADP-ribose) synthetase and mono(ADP-ribosyl)transferase" JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 267, no. 3, 25 January 1992, pages 1569-1575, XP000574735 cited in the application see the whole document	1,15-103
A	WO 95 24379 A (CANCER RESEARCH CAMPAIGN TECHNOLOGY LIMITED) 14 September 1995 see claims	1,15-103
A	US 5 589 483 A (WEST MICHAEL D) 31 December 1996 see the whole document	1,15-103

## INTERNATIONAL SEARCH REPORT

Int. application No.

PCT/US 98/18184

### Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1.  Claims Nos.: **63-76 and 78-103**  
because they relate to subject matter not required to be searched by this Authority, namely:  
**Remark:** Although claims 63-76 and 78-103  
are directed to a method of treatment of the human/animal  
body, the search has been carried out and based on the alleged  
effects of the compound/composition.
2.  Claims Nos.: **not applicable**  
because they relate to parts of the International Application that do not comply with the prescribed requirements to such  
an extent that no meaningful International Search can be carried out, specifically:  
**see FURTHER INFORMATION sheet PCT/ISA/210**
3.  Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

### Box II Observations where unity of invention is lacking(Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1.  As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2.  As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3.  As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4.  No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

The additional search fees were accompanied by the applicant's protest.

No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Claims Nos.: not applicable

The search revealed such a large number of particularly relevant documents, in particular with regard to novelty, that the drafting of a comprehensive search report is not feasible. The cited documents are considered as to form a representative sample of the revealed documents, duly taking into account their relevance with respect to the subject-matter as illustrated by the examples.

**INTERNATIONAL SEARCH REPORT**

Information on patent family members

International Application No

PCT/US 98/18184

Patent document cited in search report		Publication date	Patent family member(s)		Publication date
US 3759924	A	18-09-1973	FR	2081572 A	10-12-1971
			AT	303042 B	15-10-1972
			BE	764133 A	13-09-1971
			CA	933928 A	18-09-1973
			CH	521347 A	15-04-1972
			DE	2112026 A	23-09-1971
			DK	126000 B	28-05-1973
			FI	49034 B	02-12-1974
			GB	1285016 A	09-08-1972
			IE	35209 B	10-12-1975
			NL	7102897 A	14-09-1971
			SE	360655 B	01-10-1973
			ZA	7101602 A	24-11-1971
EP 0539805	A	05-05-1993	AT	157656 T	15-09-1997
			AU	660726 B	06-07-1995
			AU	2747192 A	06-05-1993
			CA	2081819 A	01-05-1993
			CN	1071916 A	12-05-1993
			DE	4234933 A	06-05-1993
			DE	59208852 D	09-10-1997
			DK	539805 T	23-03-1998
			ES	2108066 T	16-12-1997
			FI	924934 A	01-05-1993
			GR	3025141 T	27-02-1998
			HU	9500584 A	30-10-1995
			JP	5222002 A	31-08-1993
			MX	9206245 A	01-05-1993
			US	5354750 A	11-10-1994
			ZA	9208420 A	14-05-1993
US 3830816	A	20-08-1974	BE	729576 A	18-08-1969
			DE	1911519 A	09-10-1969
			DK	132754 B	02-02-1976
			FR	2003591 A	07-11-1969
			GB	1244501 A	02-09-1971
			JP	48022713 B	07-07-1973
			NL	6903606 A	11-09-1969
			SE	344065 B	27-03-1972
			US	3652570 A	28-03-1972
GB 1379111	A	02-01-1975	AU	5440173 A	17-10-1974
			BE	798122 A	31-07-1973
			DE	2318399 A	18-10-1973
			FR	2180066 A	23-11-1973
			IE	37478 B	03-08-1977
			NL	7305242 A	16-10-1973
			US	3895014 A	15-07-1975
			ZA	7302230 A	27-11-1974
US 5177075	A	05-01-1993	AT	117553 T	15-02-1995
			CA	1334969 A	28-03-1995
			DE	68920798 D	09-03-1995
			DE	68920798 T	18-05-1995
			EP	0355750 A	28-02-1990
			ES	2067508 T	01-04-1995
			GR	3015850 T	31-07-1995
			JP	2124874 A	14-05-1990

# INTERNATIONAL SEARCH REPORT

Information on patent family members

Intern.	Patent Application No
	PCT/US 98/18184

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
US 5177075	A	JP	2786896 B	13-08-1998
US 3247212	A	19-04-1966	NONE	
WO 9524379	A	14-09-1995	AU 693167 B AU 1856595 A CA 2184747 A CN 1143358 A EP 0749415 A EP 0879820 A JP 9510704 T US 5756510 A	25-06-1998 25-09-1995 14-09-1995 19-02-1997 27-12-1996 25-11-1998 28-10-1997 26-05-1998
US 5589483	A	31-12-1996	NONE	